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End stage renal failure is associated with a massively increased risk of cardiovascular
disease, and evidence suggests that this increase in risk begins early in the development
of chronic kidney disease. This thesis considers the hypothesis that small reductions in
glomerular filtration rate (GFR), across the population range, are associated with a
clustering of cardiovascular risk factors and increased risk of cardiovascular disease and
death. Existing methods to accurately measure GFR are difficult to perform and
unsuitable for large studies, while GFR estimated from blood creatinine or cystatin c
concentration is inaccurate.
The performance of a new method of assessing GFR, in which total plasma iohexol
clearance is measured using dried capillary blood spots, was examined in a cross-
sectional study of 81 consecutive individuals undergoing routine measurement ofGFR.
The new blood spot iohexol clearance (BSIC) method (using 3 blood spot samples)
assessed GFR accurately compared to traditional iohexol clearance using 3 timed plasma
samples (mean±standard deviation [BSIC - reference method]: 1.1±7.7 ml/min/1.73m");
prediction equations to estimate GFR from blood creatinine and cystatin c concentration
performed poorly. The results were similar when 2 blood spots (2 and 4 hours) were
used, but using only a single 4 hour blood spot resulted in some loss of accuracy.
The feasibility of using the BSIC method when the blood spot sampling is completed by
participants at home was assessed in a cross-sectional study of 111 individuals.
Following a short training, 100% of participants completed satisfactory baseline samples,
97% returned 2 timed samples through the post and 90% found the procedure acceptable.
However, 21% returned small or poor quality blood spots and there was statistical
evidence of rounding-up of the recorded sampling time. Among 106 participants with
measurements of BSIC-GFR, GFR estimated from blood creatinine, and cystatin c
concentration, one or more measures ofGFR were positively correlated with blood high
density lipoprotein cholesterol concentration, and were inversely correlated with blood
concentrations of triglyceride, C-reactive protein, fibrinogen, and homocysteine. BSIC-
GFR was not more strongly related to cardiovascular risk factors than GFR estimated
from blood creatinine concentration (eGFR). GFR estimated from plasma cystatin c
concentration was strongly related to measures of body fat, but no relationship was seen
with the other GFR measures.
In a meta-analysis of cohort studies assessing the relationship between eGFR and risk of
death and cardiovascular events, which included 4 061 003 and 1 372 820 individuals
for each outcome respectively, a 30% lower eGFR was associated with a 20-30%
increase in risk of each outcome, depending on the type of study examined. However,
there was significant heterogeneity between the studies. These overall results may
underestimate the impact of lower eGFR among those with chronic kidney disease since,
in two large studies together contributing 85% of the deaths, lower eGFR was not
associated with increased risk of death until eGFR was below 60 ml/min/1.73m2. In one
large study contributing 218 000 deaths, the relative risk of death associated with lower
eGFR was larger at younger ages, but eGFR had greater absolute impact at older ages
and among those with prior vascular disease. Because eGFR is only weakly related to
measured GFR among healthy individuals, these results may underestimate the
relationship between 'true' GFR and risk of death and vascular disease.
This work demonstrates an association between measures ofGFR and cardiovascular
risk factors, and increased risk of vascular disease, although the methods used to assess
GFR may have introduced bias. Large scale studies in which GFR is accurately
measured are needed. Using the new BSIC method for this purpose is potentially
feasible, but further work is required to ensure accuracy when the blood sampling is
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Introduction
End stage kidney disease is associated with increase risk ofcardiovascular disease
The risk of cardiovascular death among individuals with end stage kidney disease
(ESKD) receiving haemodialysis is between 10 and 100 times that ofmembers of the
general population of a similar age (1), and, among such patients, cardiovascular disease
is the leading cause of death accounting for about 60% of deaths (2). At least some of
the increased cardiovascular risk appears earlier in the natural history of kidney failure
since cardiovascular disease is already highly prevalent among individuals starting renal
replacement therapy. Among those commencing haemodialysis in the United Kingdom
(UK), 22% have a history of ischaemic heart disease (31% of those over 65 years) and
around 12% have already suffered a myocardial infarction (3), while 41% of incident
haemodialysis patients in the United States have a history of coronary artery disease (4).
In a cross-sectional study of nephrology outpatients in the UK with elevated serum
creatinine concentrations, 34% had a history of vascular disease (5) and in a similar
study in Canada the prevalence of cardiovascular disease was 39% (6). In a prospective
study of 147 nephrology outpatients with impaired kidney function in France, the
incidence of cardiovascular events was nearly 3 times that seen among members of the
general population of the same age and sex (7).
It should be noted, however, that, although individuals with ESKD are at massively
increased risk of cardiovascular disease, the pattern of vascular disease seen in these
patients is different to that observed in the general population. Routine mortality
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statistics from the US suggest that around two thirds of cardiovascular deaths in the
general population are attributed to coronary heart disease. In contrast, reports from the
United Stated Renal Data System show that, while 60% of deaths among haemodialysis
patient are attributed to cardiovascular disease, of these, only 20% are attributed to acute
myocardial infarction and 12% are attributed to stroke, leaving nearly 70% of
cardiovascular deaths attributed to 'other cardiac' causes (2). Since these data rely on
routine death certification to ascribe cause of death, there is considerable uncertainty
about the underlying pathophysiology of these 'other cardiac' deaths. While
atherosclerotic coronary artery disease may be a contributing factor in these patients,
structural heart disease also appears to be important (8). Among 433 patients assessed by
echocardiography at the initiation of dialysis, 74% had left ventricular hypertrophy
(LVH) and 15% had impaired systolic function (9) and, among haemodialysis patients,
LVH identified by echocardiography is associated with increased risk of death (10).
Arterial calcification is substantially increased among dialysis patients compared to the
general population (11). Calcification of the arterial media, which commonly occurs in
ESKD, may contribute to the development of heart failure by causing arterial stiffness
(12). Thus, controversy exists regarding whether ESKD is a pro-atherogenic state or
whether the excess risk of cardiovascular death seen in this population is related to
factors such as arterial calcification, chronic volume overload and a long exposure to
hypertension leading to structural heart disease.
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Early stages ofchronic kidney disease are defined by reduced glomerularfiltration
rate
While those with ESKD represent a clearly defined population, study of earlier stages of
kidney failure has been limited by difficulty in defining kidney disease (13). Definitions
used in epidemiological studies have included: a serum creatinine concentration above a
certain cut point (14); individuals under follow-up by a nephrologist (7); and the
recording of an appropriate International Classification of Disease code in health care
provider records (15). Since clearance of small solutes from the circulation, assessed by
the glomerular filtration rate (GFR), is regarded as the principal function of the kidneys,
the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-
KDOQI) have issued guidelines in which chronic kidney disease (CKD) is classified
according to severity on the basis ofGFR (Table 0.1) (16)). However, GFR is difficult to
measure directly and therefore, in most settings, GFR is estimated from blood creatinine
concentration (reviewed in section 1.3.1.4) (16).
GFR may be is a risk factorfor death and cardiovascular disease in unselected
populations.
Although studies have demonstrated an excess risk of cardiovascular disease in both
ESKD and in 'pre-dialysis' renal unit populations, examination ofGFR as a risk factor
for cardiovascular disease in unselectedpopulations is useful for two reasons. First,
while ESKD is associated with a massively increased risk, it is a relatively rare condition
with a prevalence of around 600 per million adults in the UK (3). If the relationship
between GFR and cardiovascular disease is continuous across the population range of
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GFR, then a larger proportion of the population at increased risk, who may benefit from
cardio-protective interventions, could perhaps be identified. Second, the finding of
excess cardiovascular risk among individuals with advanced CKD could be the result of
reverse causality in which cardiovascular disease results in renal failure. Prospective
studies among healthy populations, in which GFR is measured at baseline and related to
future cardiovascular events, are necessary to examine GFR as a determinant of
cardiovascular disease. Although no population based prospective cohort studies have
measured GFR directly, a number of studies have demonstrated a modest association
between lower GFR estimated from serum creatinine concentration (eGFR) and an
increased risk of death and cardiovascular disease (17-19). However, since eGFR is only
weakly related to 'true' GFR in healthy populations (20;21), the results of these studies
may distort the true relationship between GFR and cardiovascular risk.
Evidence suggests that lower GFR may be a causal risk factorfor vascular disease
Several lines of evidence support the hypothesis that reduction in GFR is a causal risk
factor for cardiovascular disease. First, in ESKD the substantial improvement in
mortality associated with renal transplantation (22) suggests that, in this population, at
least some of the cardiovascular risk is driven by the absence of independent renal
clearance function. Second, CKD is associated with a number of adverse cardiovascular
risk factors (23), including hypertension (24), a pro-atherogenic lipid profile (25), higher
blood concentration of inflammatory markers such as C-reactive protein (26), higher
blood homocysteine concentrations (27) and increased oxidative stress (28) (Table 0.2).
Anaemia and abnormalities in the metabolism of calcium and phosphate are common in
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CKD (29;30) and may contribute to the development of structural heart disease (12;31).
Third, in animal studies loss of GFR results in dyslipidaemia (32), hypertension (33) and
accelerated cardiovascular disease (34;35).
This thesis considers the hypothesis that small reductions in GFR, across the range of
GFR observed in the general population, are associated with a clustering of
cardiovascular risk factors which subsequently result in an increased risk of
cardiovascular disease. In addressing this hypothesis, this thesis will first consider how
GFR can best be measured in large scale epidemiological studies, before examining how
measures of GFR are related to cardiovascular risk factors and risk of cardiovascular
mortality and morbidity.
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Kidney damage with normal or increased GFR









Chronic kidney disease is defined as either kidney damage or GFR (glomerular filtration rate) <60 ml/min/1.73m2 for
> 3 months. Kidney damage is defined pathological abnormalities or markers of damage including abnormalities in
blood or urine tests or imaging studies
Reproduced from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI)
clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (16)
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1.1 Introduction
Glomerular filtration rate (GFR), defined as the volume of fluid filtered from the renal
glomerular capillaries into Bowman's space per unit of time, is regarded as the principal
measure of kidney function (16). This thesis is concerned with the relationships among
GFR, cardiovascular risk factors, and cardiovascular disease; how these relationships
might be affected by the method used to measure GFR; and the development of an
accurate GFR method suitable for large scale epidemiological studies. Before
considering these issues, this chapter describes existing methods for measuring GFR, the
suitability of these methods for large scale studies, and potential sources of error. Since
this thesis examines the relationship between GFR and cardiovascular risk in adults, the
measurement of GFR in children is not discussed here.
GFR is equivalent to the urinary clearance of a tracer substance provided that the tracer
is physiologically inert, is freely filtered at the glomerulus, and is neither secreted nor
reabsorbed by the renal tubules (71). Since the 1930s, the gold standard method of
assessing GFR has been the measurement of renal inulin clearance using multiple timed
urine and blood samples collected while administering an intravenous inulin infusion
along with oral, or intravenous, fluids to ensure constant urine flow rates (72). Since
then a number of techniques have been developed to assess GFR from the appearance of
exogenous tracer substances in the urine, or the disappearance of such substances from
the plasma. In this thesis, these methods are referred to as 'direct GFR methods'. More
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recently, methods have been developed to estimate GFR from a single measurement of
the plasma concentration of endogenous substances which are filtered by the glomerulus,
referred to here as 'indirect GFR methods'.
1.2 Direct GFR methods
The 'direct GFR methods' vary in terms of the clearance calculation method (urinary
clearance or total plasma clearance), the choice of GFR tracer substance and the way in
which that substance is administered (continuous intravenous infusion, bolus
intravenous injection or subcutaneous injection).
1.2.1 Clearance calculation methods
1.2.1.1 Urinary clearance methods
Urinary clearance of a GFR tracer compound can be calculated from a timed urine
collection and appropriate plasma sample using the classic formula (71);
a) Clearance (ml/min) = UxV/Pxt
(Where U is the concentration of the tracer in the urine, V is the volume of urine in ml, P
is the plasma concentration of the tracer and t is the number ofminutes for which the
urine was collected).
If the tracer has been administered by continuous infusion, the plasma sample may be
taken at any time during the urine collection period. If a bolus injection of tracer has
been given, the plasma sample can be collected at the mid point of the timed urine
collection or an average of plasma tracer concentrations measured at the beginning and
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end of the urine collection period can be used. Potential sources of error in this method
include incomplete bladder emptying and incorrect timing of the plasma or urine
samples, along with laboratory variation in the measurement of the concentration of the
tracer blood and urine. In order to minimize the potential effect of incomplete bladder
emptying, traditional GFR protocols require the insertion of a urinary catheter (although,
more recently, this has been reserved for individuals in whom bladder ultrasound
demonstrates a residual urinary volume (73)). Errors can be reduced by collecting
several timed urinary and blood samples and taking an average of the results since
considerable variability is seen between serial clearance periods during the same test. In
the Modification of Diet and Renal Disease study in which renal clearance ofl25-
Iothalamate was measured in around 1600 participants enrolled in the baseline
assessment, 4 clearance periods were used. The coefficient of variation among the 4
clearance periods was 9.4% (73).
1.2.1.2 Total plasma clearance methods
Following a single injection, clearance of an exogenous tracer substance from the
plasma can be estimated from the dose of administered tracer compound and the area
under the plasma disappearance curve (AUC) according to the formula (74);
b) Clearance = dose / AUC
Provided the tracer substance has little or no extra-renal clearance, clearance from the
plasma is approximately equivalent to GFR.
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Following an intravenous injection, the plasma concentration of GFR tracers fall
exponentially as the tracer diffuses into the extra-vascular space (the rapid equilibration
phase) and thereafter declines linearly (75). Complete equilibration between the plasma
and the extra-vascular space takes 2-8 hours depending on the volume of distribution of
the tracer compound and the size of the individual (75;76). Direct measurement of the
AUC requires a large number of plasma samples, but the area under the curve can be
estimated from 2 or 3 plasma samples by first assuming a one compartment model using
formula c.
c) Clearance (p = Dose / (C0 / k)
(where C0 is the intercept and k the slope of the least squares regression line of Ln
[plasma tracer concentration] against time).
Then a mathematical adjustment can be made to account for the rapid equilibration
phase using the Brochner-Mortensen (77) formula;
d) Clearance (finai) = 0.990778 x Clearance (p-0.001218 x Clearance (p2
In order to simplify the procedure further, a number of formulae have been developed to
estimate total plasma clearance using just one plasma sample (78). These methods use
an estimate of the volume of distribution and the administered dose of the tracer
substance as a surrogate for the tracer concentration in the blood at time zero. The most
commonly used one sample method, developed by Jacobsen, is described in the
following formulae (79);
e) Clearancep) = (Ln [dose / Ct x V]) / (0.0016 + t/V)
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(where t= sample time, Ct = tracer concentration at time t, V= volume of distribution of
tracer).
This estimate is then adjusted by a factor, 'm', which is dependent on the initial
clearance value.
f) m = 0.991 - 0.00122 x Clearance(i)
g) Clearance (final) = (Ln [dose / Ct x V/m]) / (0.0016 + mt/V)
Potential sources of error for all plasma clearance methods include the administration of
an incorrect dose of tracer (some protocols advocate weighing the syringe containing the
tracer prior to injection to ensure exact measurement of dose), incorrect timing of
plasma samples and extra-renal elimination of the tracer, along with laboratory variation
in the plasma tracer assay. In conditions such as ascites, which are associated with
marked alterations in the distribution of fluid within the body, the rapid elimination
phase may be different to that assumed in the Brochner-Mortensen method, resulting in
additional error when this calculation method is used (80). In addition, among
individuals with very low GFR, a late (usually 24 hour) sample is required in order to
accurately estimate the area under the plasma curve (81). Since the one sample methods
estimate the volume of distribution of the marker substance from anthropomorphic
measurements such as weight (78;79), variation in body composition could result in
additional error.
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1.2.2 Method of tracer administration
The classical inulin clearance protocol requires the administration of an intravenous
infusion to establish constant plasma insulin concentrations (72). However,
administration of a single intravenous injection is a simpler and more practical
procedure for patients and staff and is widely used with both total plasma clearance (82-
84) and renal clearance techniques (85;86). Subcutaneous injection of tracer compound
has also been used in conjunction with renal clearance techniques (85).
1.2.3 Choice ofexogenous GFR tracer
Although the fructose polymer inulin has been used for the assessment of GFR since the
1930s (72), the relatively high cost and time consuming chemical analysis techniques
have prompted the use of alternatives tracers. Radio-labelled markers such as chromium-
51 ethylene diamine tetra-acetate (51Cr-EDTA), "mTc-diethylene-triamine-penta-acetic
acid (99mTc-DTPA) or l25I-Iothalamate also fulfill the criteria for a GFR tracer and,
being relatively easily measured using a scintillation counter, have been used for this
purpose since the 1960s (82;87;88). However, the strict procedures required for safe
handling, storage and disposal of radio-isotopes are a major disadvantage in the use of
these compounds. More recently, both ionic (e.g. iothalamate) and non-ionic (e.g.
iohexol or iopromide) contrast media have been used to measure GFR (76). The plasma
concentration of these agents can be reliably measured by high performance liquid
chromatography (HPLC) (89) or X-ray fluorescence analysis (90); although the later
method is less accurate when small volumes of tracer are administered (91). Ionic and,
to a lesser extent, non-ionic contrast media have been associated with adverse reactions
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during angiography or radiological studies (typical dose of about 100ml) (92;93),
although data suggest that adverse reactions are very rare when small doses of around
5ml are used (94). The characteristics of the individual GFR tracer compounds are
summarized in table 1.1.
1.2.4 Adjustmentfor body surface area
GFR is directly related to intravascular volume, and therefore body size (71). To allow
meaningful comparison between individuals, GFR is usually standardised to a body
surface area (BSA) of 1.73 m2. Body surface area is difficult to measure directly, and is
usually calculated from measurements such as height and weight using a prediction
equation such as the commonly used formula by Dubois and Dubois (95);
BSA = 0.20247 x height (m) 0 725 x weight (kg) 0425
1.2.5 ""'Tc-diethylene-triamine-penta-acetic acid(>>mTc-DTPA) renography
A less invasive method ofmeasuring renal "mTc-DTPA clearance has been proposed, in
which the uptake of "mTc-DTPA in both kidneys measured by renography 2-3 minutes
after an intravenous injection is used to estimate GFR (96). This method does not require
urine or blood sampling, and can be completed in a short time period. Unfortunately,
when compared to total plasma "mTc-DTPA clearance (97) and 5,Cr-EDTA clearance
(98), and renal clearance of inulin (99), "mTc-DTPA renography has very poor accuracy.
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1.2.6 Use ofdirect GFR methods in epidemiological studies
Direct methods of assessing GFR are difficult to perform and time consuming, usually
requiring that the participant spend at least 4 hours at the hospital, undergo multiple
venepuncture and, in some protocols, collect timed urine collections which may require
bladder catheterisation. When radio-labelled GFR tracers are used, strict protocols,
which often include restrictions for participants after the test is completed, are required
to ensure the safety of staff, participants and the general public. Thus, using existing
methods, direct measurement of GFR in a large scale population based epidemiological
study would be impractical.
In addition, because of short term changes in true GFR and measurement error, there is
considerable intra-individual variability in directly measured GFR. For example, among
individuals enrolled in the Modification of Diet in Renal Disease study in whom renal
clearance of 125-lothalamate was measured 3 months apart, the median coefficient of
variation was 6.3% (73).
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1.3 Indirect GFR methods
Plasma concentrations of endogenous substances which are filtered by the glomerulus,
such as creatinine or the low molecular weight protein, cystatin c, are inversely
proportional to GFR: Therefore, GFR can be indirectly estimated from single
measurements of the blood concentration of these 'GFR markers'.
1.3.1 Blood creatinine as a marker ofGFR
The observation that creatinine is eliminated from the body by glomerular filtration led
to the development of creatinine clearance as a measure of GFR in the 1930s (100).
Since then, measurement of blood creatinine concentration has become the most
commonly performed assessment ofGFR. The physiology of creatinine metabolism, and
methods used to assess GFR from blood creatinine concentration are described below.
1.3.1.1 Creatinine production
Creatinine has no known biological function and is generated by spontaneous
degradation of creatine and phosphorylcreatine (figure 1.1) (101). Creatine is
synthesised in liver, kidneys and pancreas from arginine by 2 enzymically mediated
reactions; first, the conversion of arginine and glycine to guanidinoacetate and ornithine,
and then the methylation of guanidinoacetate to form creatine (figure 1.1) (101).
Creatine is then transported to muscle, and other tissues, where it is phosphorylated to
form the high energy compound phosphocreatine, which plays an important part in
muscle contraction (101). About 2% of total body creatine, which is predominantly
located in muscle, spontaneously converts to creatinine each day (75). Creatinine
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production, therefore, is heavily dependent on muscle mass, but remains relatively
constant within an individual over the short term. Dietary intake ofmeat can, however,
result in an increase in blood creatinine concentration and 24 hour creatinine excretion
of 10-20% (102; 103).
1.3.1.2 Creatinine elimination
Creatinine is freely filtered by the glomerulus and therefore blood creatinine
concentration is inversely proportional to GFR (104) while urinary creatinine clearance
correlates with GFR (100). However, since small amounts of creatinine are excreted by
the renal tubules, creatinine clearance generally exceeds inulin clearance by 10-20%
(100;104). The ratio between creatinine and inulin clearance is considerably higher
among individuals with substantially reduced GFR (104). Among individuals with very
high GFR, tubular re-absorption of creatinine may lead to an underestimation ofGFR by
creatinine clearance (105). Cimetidine, which inhibits tubular creatinine secretion, is
sometimes administered as part of a creatinine clearance protocol (104).
In advanced chronic kidney disease (CKD), blood creatinine concentrations are
substantially lower than that predicted by a reciprocal relationship with GFR, as a result
of both increased tubular creatinine secretion and extra-renal removal of creatinine from
the circulation. In stage 5 CKD (GFR < 15 ml/min/1.73m2 (16)), between 16 and 66% of
generated creatinine disappears from the body by mechanisms other than excretion in
the urine or faeces (101). This 'creatinine deficit' is thought be the result of increased
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degradation of creatinine either by 'creatininase' producing gut bacteria or by oxidative
creatinine degradation pathways (101).
1.3.1.3 Measurement of creatinine concentration in blood and urine
Creatinine concentration in plasma, serum or urine can be measured using an alkaline
picrate ('Jaffe') reaction, enzymatic methods, high performance liquid chromatography
(HPLC) or isotope-dilution mass spectrometry (IDMS) methods. The concentration of
creatinine in plasma and serum is roughly equivalent and is used interchangeably (106).
Originally described by Jaffe in 1886 (107), the reaction between creatinine and picrate
irons which, under alkaline conditions, results in an orange-red complex, forms the basis
of creatinine estimation in most routine laboratories. This reaction is not specific for
creatinine as a number of substances also undergo the Jaffe reaction (e.g. glucose,
acetone, cephalosporins, pyruvate) (100; 108). A large number ofmethods, involving
kinetic assays and the addition of variety of specific reagents, have been developed
aimed at reducing interference from these non-creatinine chromogens (109) although
interference from such substances can still lead to overestimation of blood creatinine
concentration by as much as 15-25% depending on the specific reagents used (108).
In order to overcome the lack of specificity associated with the Jaffe based assays, a
number ofmulti-step enzymatic methods have been developed (100; 108). Although
more specific than the modified Jaffe methods, interference from non-creatinine
substances can still occur with enzymatic methods (110), and their greater cost and
longer run times have limited the use of these methods in clinical practice. A number of
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HPLC methods for measurement of creatinine have been developed which, although
rarely used in clinical practice, are more specific than conventional methods (108).
IDMS methods, which have very high specificity and precision, have been developed for
measurement of creatinine in reference materials, but are available in only a few
specialized laboratories worldwide (108).
Considerable variation exists between laboratories in the measurement of creatinine. A
survey of 5624 laboratories found that the 50 instrument-method combinations used
measured creatinine with a bias of -5.3 to 27.4 gmol/1 compared to the reference
laboratory IDMS method (111). A program to standardize all laboratory creatinine
methods to an IDMS reference method has been proposed (108). However, although
such standardisation would remove the bias associated with some creatinine methods or
instruments, lack of specificity could still result in erroneous measurement of serum
creatinine concentration for an individual. Inter-laboratory quality-control programs
suggest that within laboratory coefficients of variation are between 2 and 8.5% at a
blood creatinine concentration of 88.4 pmol/1 for most creatinine assays (108).
Creatinine is stable for up to 4 days in whole blood stored at 4 °C, but each day at which
whole blood remains at room temperature increases subsequent measurement of plasma
concentration by about 5% (112). The concentration of creatinine concentration in serum
stored at -80 °C is unaffected by thawing and refreezing the sample (113).
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1.3.1.4 Estimation of GFR from blood creatinine concentration
Since GFR is approximately proportional to the reciprocal of blood creatinine
concentration, mathematical formulae have been used to predict GFR from the
concentration of creatinine in the blood. These formulae also include variables such as
weight, height, age or sex, which are related to muscle mass and so correlate with blood
creatinine concentration. Published formulae to estimate GFR from blood creatinine
concentration are shown in table 1.2. Flowever, this thesis will principally consider the 2
most commonly used formulae; the Cockcroft Gault formula and the abbreviated
Modification ofDiet in Renal Disease (MDRD) formula.
The abbreviated MDRD formula (table 1.2) was developed to predict body surface area
normalised renal clearance of 125lothalamate among 1628 individuals with CKD
screened for the Modification of Diet in Renal Disease study who had a mean GFR of 40
ml/min/1.73 m2 (114). Studies assessing the performance of the MDRD formulae are
summarized in table 1.3.
The Cockcroft Gault formula (table 1.2) was developed to predict creatinine clearance,
without adjustment for body surface area, among male hospital inpatients with a mean
creatinine clearance of 73 ml/min/1.73m2 (115). The estimate must, therefore, be
adjusted for body surface area to predict body surface area normalised GFR. Since
creatinine clearance generally overestimates GFR because of tubular creatinine secretion,
it has been suggested that the estimate produced by the Cockcroft Gault formula
multiplied by a factor of 0.85 better reflects GFR (116) although, in practice, this
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adjustment is often not made. Studies assessing the performance of the Cockcroft and
Gault formula are summarised in table 1.4.
1.3.2 Creatinine clearance as a measure ofGFR
Creatinine clearance, calculated according to formula 'a' in section 1.2.1, has been used
as a measure ofGFR since the 1930s (100). Typically, urine is collected for 24 hours
and a blood sample is taken during this period. Sources of error in this method include
inter-individual variability in tubular creatinine secretion and, more importantly, failure
to accurately collect a precise timed urine collection. A large number of studies have
confirmed that, as a result of these problems, measured creatinine clearance does not
represent an advantage over GFR estimated from a single measurement of blood
creatinine concentration in terms of accuracy (117-127), while representing a substantial
disadvantage in terms of convenience.
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1.3.3 Cystatin C as a marker ofGFR
Cystatin c, also known as gamma trace protein, was proposed as an alternative to
creatinine as an endogenous marker ofGFR in the 1980s (128) and since then a number
of studies have suggested that blood concentration of cystatin c has better diagnostic
accuracy than blood creatinine concentration (129; 130).
1.3.3.1 Physiological functions of cystatin c
Cystatin c is a low molecular weight protein and a potent inhibitor of the papain type
cysteine protease enzymes, known as cathepsins (75). The cathepsins are part of a
broader group of protease enzymes which also include the serine proteases, matrix
metaloproteases and the aspartate proteases. They are most stable at an acidic pH and are
active within lysosomes where they break down unwanted proteins; however they can
also act outside lysosomes and are involved in a number of specific physiological areas.
Cathepsins K, S and L have been shown in vitro to degrade various components of the
intracellular matrix ,such as elastin, laminin, fibronectin and type I collagen (131; 132).
Cathepsin K is produced by osteoclasts and is involved in bone remodelling (133).
Cathepsin S is involved in the intracellular trafficking ofMHC class II molecules and
therefore regulation of antigen presentation (134). The various cathepsins are
differentially expressed in different cell types and their expression and secretion in
experimental cell lines can be induced by various cytokines (135). Cystatin c is
expressed by all nucleated cells and the gene promoter is of a housekeeping type (136).
However, in experimental cell lines, the expression and secretion of cystatin c can be
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effected by inflammatory cytokines (135), steroid hormones (137) and lipopolysacharide
(138). Cystatin c has also been shown to antagonise TGF-P by a cathepsin independent
mechanism suggesting that it may have physiological functions other than cathepsin
inhibition (139).
1.3.3.2 Cystatin c production
While few studies have directly assessed the determinants of cystatin c production, a
number of factors, other than GFR, are related to an individual's usual long term blood
cystatin c concentration. Mean plasma cystatin c concentration among healthy non
smoking individuals under 65 is around 0.7±0.1 mg/1, with slightly higher concentration
in men than women (140). In a large community sample, smokers and those with greater
body weight had higher plasma cystatin c concentrations, after adjustment for measured
creatinine clearance (141). Six cystatin c gene polymorphisms have been identified
which are related to blood cystatin c concentration (142; 143). In one study, each of the
mutant alleles (82C,78G,5A,4C) was associated with a lower cystatin c concentration
(142). There was linkage disequilibrium and a mutant haplotype (82C,78G,5A,4C) was
associated with 0.03-0.04 mg/1 lower concentration of cystatin c per copy. In this study
of 155 Swedes, -35% were heterozygous and -6% were homozygous for this mutant
haplotype. In another study (143), for each of the mutant alleles (148G, 82C,5A,4C) one
copy was associated with about 0.04-0.1 mg/1 lower cystatin c concentration. A mutant
haplotype (82C, 5A,4C) was associated with -0.06 mg/1 lower blood cystatin c
concentration per copy. In this study of 1013 patients with coronary heart disease, -4%
were homozygous and 31% heterozygous for this mutant haplotype.
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1.3.3.3 Short term changes in blood cystatin c concentration
Plasma concentration of cystatin c is increased in hyperthyroidism and decreased in
hypothyroidism based on serial measurements in patients with thyroid disorders at
presentation and after recovery (144; 145). The magnitude of the change in blood
cystatin c concentration in these studies was around 0.2mg/l for both hyo- and hyper¬
thyroidism. Subclinical hypo- and hyper- thyroidism is associated with a smaller change
in blood cystatin c concentration of around 0.1 mg/1 (146). Several studies have shown
an increase in blood cystatin c concentration following the administration of large doses
of exogenous steroids (147-149) but none have adjusted for measured GFR.
Only four small clinical studies have assessed serial cystatin c measurements in response
to acute vascular disease or other systemic insult and none of these measured GFR. Noto
et al (150) measured blood cystatin c and creatinine concentration in 61 patients
presenting with acute myocardial infarction (Ml), 61 patients presenting with acute
coronary syndrome without confirmed MI and 61 healthy volunteers. Mean cystatin c
concentration was 0.05 mg/dl lower in those presenting with acute MI than the healthy
controls but subsequently increased. The cystatin c to creatinine ratio in cases ofMI was
1.02 at admission a 1.14 prior to hospital discharge. Gupta-Malhotra M et al (151) found
that serum cystatin c concentration was lower among 17 children presenting with acute
Kawasaki's disease compared to control children and that the serum cystatin
concentration increased after treatment of the disease. Two studies reported a fall in
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cystatin C concentration in the first 24 hours following total hip replacement (152) and
hysterectomy (153). However both studies were small and neither paper report the
quantity of intravenous fluid administered. There is no evidence of variation in plasma
cystatin c levels with circadian rhythm (154).
1.3.3.4 Elimination of cystatin c
Clearance of cystatin c from the circulation is almost entirely through glomerular
filtration (155). Once filtered, cystatin c undergoes complete proteolysis within the
tubular cells (155). Plasma cystatin c concentrations are therefore inversely proportional
to GFR (156), but assessment of GFR from the urinary clearance of cystatin c is not
possible.
1.3.3.5 Measurement of cystatin c concentration in plasma and serum
Plasma concentration of cystatin c is measured by immunoassay, most commonly either
by Particle-Enhanced Turbidometric Immunoassay (PETIA) or by Particle-Enhanced
Nephelometric Immunoassay (PENIA) (75). Some studies have suggested that PENIA
assays have better reproducibility at higher plasma cystatin c concentrations (157) and
are less susceptible to interference from other substances such as bilirubin (158) than the
PETIA assays. Plasma cystatin c concentrations are similar, or very slightly lower (3%),
in serum than plasma (156; 157; 159). There is currently no standardisation of cystatin c
methods between laboratories.
Serial measurements in healthy volunteers with repeated analysis of samples
demonstrate that the coefficient of variation attributable to biological variation is around
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13%, while that attributable to analytical variation is around 9% (160). Blood cystatin c
concentrations are stable in whole blood stored at room temperature for up to 4 days
[personal communication, Clinical Trial Service Unit laboratory],
1.3.3.6 Estimation ofGFR from blood cystatin c concentration
A number of formulae have been developed to predict GFR from blood cystatin c
concentration (table 1.5). As blood cystatin c concentration is less dependent on muscle
mass than blood creatinine concentration (140), these formulae mostly involve only
constant terms. All the formulae, except for one (161), were developed to predict GFR
standardised to 1.73m2 body surface area. Studies assessing the performance of cystatin
c formulae are summarized in table 1.6. In one study GFR estimated from blood
concentrations of both cystatin c and creatinine was more closely related to the reference
GFR than estimates using each marker alone (r2 of 0.891 for the equation including both
markers compared to 0.825 for the MDRD formula and 0.852 for a cystatin c based
formula) (162).
1.3.4 Other endogenous GFR markers
A number of other endogenous GFR markers have been proposed, including other low
molecular weight proteins and urea. Urea, a nitrogen-containing by product of protein
metabolism, is predominantly cleared from the circulation by the kidneys and the
concentration of urea in serum or plasma can easily quantified by most laboratory auto-
analysers (75). However, significant 'back diffusion' of filtered urea from the renal
tubules into the circulation occurs and, more importantly, blood concentrations of urea
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are substantially affected by non-renal factors such as diet and hepatic synthesis limiting
its use as a GFR marker (75).
Beta-2-microglobulin is associated with the histocompatibility antigen complex on the
surface of nucleated cells and is shed from cells during cellular turnover. Like cystatin c,
P2-microgloblin is removed from circulation by glomerular filtration and degraded in the
proximal tubules (75). Blood beta-2-microglobulin concentrations are inversely
proportional to GFR (128) and show similar diagnostic accuracy to blood cystatin c or
creatinine concentrations (163; 164). However, blood concentrations of |32-microglobulin
are massively elevated in a number of haematological malignancies and, to a lesser
extent, in acute inflammation (165) limiting its use as a GFR marker. Another low
molecular weight protein, retinol-binding protein, has been proposed as a GFR marker,
but plasma concentrations correlate poorly with directly measured GFR (128; 163).
1.3.5 Use ofindirect GFR methods in epidemiological studies
Since indirect estimation ofGFR requires only a single blood sample, it can be easily
undertaken in large scale epidemiological studies, and can be retrospectively analysed in
stored blood from existing cohorts (166). Cystatin c is stable for several days in whole
blood at room temperature and is therefore suitable for use in population surveys in
which blood samples are returned to the research centre by post. These methods,
therefore, have substantial practical advantages for large scale epidemiology. However,
there are a number of disadvantages associated with their use in this setting.
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First, the GFR estimates produced by creatinine based prediction equations are critically
dependent on calibration of the creatinine assay (167) (section 1.3.1.3). Calibration
differences which are relatively constant across the range of blood creatinine
concentration have a greater impact on estimated GFR at higher GFR levels when the
calibration difference represents a greater proportion of the creatinine value (167).
Creatine assay calibration can have substantial effects on the estimated prevalence of
chronic kidney disease (CKD) (16) classified by estimated GFR: In the 3rd National
Health and Nutrition Estimation Survey, a large population survey in the United States,
the prevalence ofCKD (defined as GFR estimated by the MDRD formula of
<60ml/min 1.73m2) among non-diabetic adults was 13% (168). This figure fell to 4%
assuming a 17.7 pmol/1 over-estimation of blood creatinine values (168) while in fact the
laboratory used for this study measured blood creatinine concentration 20 pmol/1 higher
than the laboratory used to develop the MDRD formula (167). Such laboratory
calibration differences make comparison of the prevalence and associations of reduced
eGFR between study populations unreliable. The use of a revised version of the MDRD
formula for use with creatinine assays which have been calibrated to a isotope-dilution
mass spectrometry method may help to overcome these problems in future studies (table
1.2) (169). Laboratory methods also have substantial effect on GFR estimates calculated
from blood cystatin c concentration (161) but, since this assay is only used in clinical
practice in a few centres, standardisation between laboratories has not been addressed.
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Second, the MDRD, Cockcroft-Gault and cystatin c equations have not been validated in
some populations, such as individuals from the Indian subcontinent, making
comparisons of the impact of absolute eGFR values between ethnic groups difficult.
Third, and most importantly, for an individual, GFR estimated from blood creatinine
concentration and cystatin c can be highly discrepant from 'true' GFR (Tables 1.3, 1.4
and 1.6). In an epidemiological study in which these equations are used to assess the
relationship between GFR and a particular outcome, this would tend to bias the results
towards the null (170).
Fourth, the inclusion of demographic variables, such as age, sex and weight, in the
creatinine-based predictions has implications for the use of these equations in research
studies. Bias may be introduced when estimated GFR is related to variables which are
included in the equation (171). For example, in a large cross-sectional study, a strong
relationship was found between weight and GFR estimated by the Cockcroft-Gault
formula, when little or no relationship was observed between weight and GFR estimated
from the MDRD formula or measured creatinine clearance (171). In cohort studies
where analyses are adjusted for age, sex and other variables, the effect of this
'colinearity' is likely to be small. However, in such analyses, GFR estimated from blood
creatinine concentration by standard prediction equations does not provide any more
information than serum creatinine concentration. Since GFR can be estimated from
blood cystatin c concentration with similar accuracy to the creatinine based prediction
equations but without inclusion of demographic variables in the formula, this may
provide more useful information for epidemiological studies.
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Fifth, non renal influences on the concentration of an endogenous marker may introduce
specific biases. For example, since creatinine production is directly related to muscle
mass (101), loss ofmuscle mass during chronic illness may be associated with low
creatinine concentrations. Among elderly individuals, a J shaped relationship is observed
between blood creatinine concentration and non-vascular mortality where individuals
with both high and low blood creatinine concentration are at increased risk (172). This J
shaped curve could represent an association between low muscle mass and increase risk
of non-vascular death, and is not observed with blood concentration of cystatin C (172),
which less influenced by body composition than serum creatinine concentration (140).
Thus, the use of indirect GFR methods in epidemiological studies is associated with a
number of problems, of which the most limiting is the weak relationship observed
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Figure 1.1: Generation of creatinine in humans
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methionine homocysteine




Adapted from Wyss et al (101)
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Chapter 2: Accuracy of a novel GFR method (blood spot iohexol
clearance |BSIC]) and comparison with blood creatinine or
cystatin c based equations
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2.1 Study aims
Primary aims of the study;
■ To assess the accuracy of a novel method ofmeasuring GFR in which iohexol
clearance is measured using 3 dried capillary 'finger-prick' blood samples.
■ To determine whether the blood spot iohexol clearance (BSIC) method represents
a substantial advantage in terms of test accuracy over creatinine or cystatin c
prediction equations, both among those with 'reduced GFR' (<60 ml/min/1,73m2)
and those with 'preserved GFR' (>60ml/min/l ,73m2).
Secondary aims of the study;
■ To assess whether the number of sampling points used in the BSIC method can
be reduced without loss of accuracy.
■ To assess the potential impact ofmisreporting of sample collection time on test
accuracy.
■ To determine whether measurement of individual haematocrit is necessary to
accurately measure iohexol clearance using dried whole capillary blood samples.
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2.2 Methods
2.2.1 Participant recruitment and data collection
Sixty consecutive patients referred for assessment ofGFR and 21 healthy volunteers
were recruited at the South West Thames Institute for Renal Research, St Helier
Hospital, Surrey, UK. Participants were instructed to abstain from caffeine,
paracetamol, smoking and high protein foods for 6 hours prior to and during the
study visit. After giving written informed consent, weight and height were recorded
and baseline venous blood samples were taken for measurement of haematocrit,
serum creatinine and serum cystatin C concentrations. A bolus of 5ml of 300mg/ml
iohexol (Omnipaque® 300, Nycomed Amersham pic, Buckinghamshire, UK) was
administered via an intravenous cannula. Venous blood, sampled from the
contralateral arm, and capillary blood spots were taken by one of two trained
researchers approximately 2, 3 and 4 hours later and the precise times recorded.
Capillary blood was drawn using a 'Unistik 2 normal' disposable lancet (Owen
Mumford, Oxford, UK). Pressure was applied to the finger to form a large droplet,
which was then dropped onto filter paper (Schleicher and Schuell Grade 903, Dassel,
Germany) to obtain a spot of at least 7mm in diameter. The study staffwere trained
to drop only one spot of blood onto each sample area, as layering of blood within a
sample can affect the volume ofblood contained in a given area of the paper, thereby
introducing error. To simulate outpatient conditions, the capillary blood spots were
dried and sent to the laboratory through the post. The study was conducted in
compliance with the Declaration of Helsinki and approval for the study was obtained
from the Local Research Ethics Committee.
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2.2.2 Laboratory analysis
Laboratory analysis was conducted at the South West Thames Institute for Renal
Research, St Helier Hospital, Surrey, UK. Serum creatinine concentration was
measured using a modified kinetic Jaffe reaction (Advia 1650, Bayer, Newbury,
Berkshire, UK) and serum cystatin C concentration by a particle-enhanced
turbidometric assay (Dako PETIA kit K0071, Denmark) adapted for use on Advia
1650 (Bayer Newbury, Berkshire, UK). For analysis of iohexol concentration in
serum, 56pl of the serum sample was treated with 850gl 5% perchloric acid. For
analysis of iohexol concentration in dried capillary blood, a 6.3mm punch of the
blood spot (assumed to contain 11.2pl of blood) was treated with 170gl 5%
perchloric acid and then vortexed for 3 min, ultrasonicated for 15min, incubated for
30 min at room temperature, and spun at 14000g for 10 min (211). Iohexol
concentration in these treated samples was then estimated by reverse-phase High
Performance Liquid Chromatography (HPLC) (Column - Nucleosil 120; C18 plus
5cm guard column at 30°C; pump- 1.5ml/min; detector wavelength 254nm; range
0.05). The intra- and inter-assay coefficients of variation for the HPLC assay for
plasma samples were 2.7% and 6.0% respectively.
Whole blood iohexol concentration in the capillary blood spot was corrected for the
venous blood haematocrit to estimate the equivalent serum concentration using the
formula




2.2.3.1 Reference method (iohexol clearance from venous samples)
GFR measured by iohexol clearance using 3 serum samples (2, 3 and 4 hours) and
corrected for Body Surface Area (BSA; estimated by the Dubois-Dubois formula
(95)) was considered the reference method for this study. This was calculated by a
one compartment model using the formulae (a)-(c) below (89).
(a) Clearance p) (ml/min) = Dose (mg/ml) / (CJk)
Where C0 is the intercept and k the slope of the least squares regression line of Ln
[iohexol concentration (mg/ml)] against time (minutes).
(b) Clearance (2) (ml/min) = 0.990778 x Clearance p)— 0.001218 x Clearance p2
(c) GFR(ml/min/1.73m2) = Clearance p) (ml/min) x 1.73 /BSA (m2)
2.2.3.2 Test methods
(i) Iohexol clearance from capillary blood spots
In the main analysis the 3-spot (2, 3 and 4 hours) and 2-spot (2 and 4 hours) iohexol
clearances were calculated using formulae (a)-(c) above. The 1-spot iohexol
clearance was calculated from a single capillary blood spot taken at 4 hours using the
formulae (d)-(g) below (79). Since it is not possible to estimate the slope of the
iohexol elimination curve using blood iohexol concentration taken at a single time
point, this formula employs a function of the estimated volume of distribution of
iohexol and the dose of iohexol administered as a surrogate for the concentration of
iohexol in the blood at time zero.
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In[Do.se iohexol (mg)/{Ct xK)]
(d) Clearance (i) (ml/min) = 0.0016 + t/V
where t = sample time (minutes), Ct = iohexol concentration (mg/ml) at time t, and
the volume of distribution (ml), V =(187 x weight (kg)) + 732 (ml) (212). This
estimate of iohexol clearance requires adjustment by a factor which is dependent on
the value of the estimate, given as m in the equations below.
(e) m = 0.991 - 0.00122 x Clearance (j)
In[Do.se iohexol (mg)/(Ct x V /m) ]
(f) Clearance (2) (ml/min) = 0.0016 + mt/V
(g) GFR (ml/min/1.73m2) = Clearance (2) (ml/min) x 1.73 /BSA (m2)
In a secondary analysis, the iohexol clearance calculation (formulae (a)-(c) above)
was repeated using blood spots taken 2 and 3 hours after the injection, and 3 and 4
hours after the injection.
(ii) Prediction equations
In the main analysis, GFR was estimated from the serum concentration of creatinine
(pmol/1) and cystatin C (mg/L) using the following equations:
MDRD formula (114)
GFR=186 x [Creatinine / 88.4] 154 x [age] ~0203 x [0.742 iffemale] x [1.212 if
black]
Cockcroft and Gault formula (115)
GFR = (140-age) x weight (kg) x (1.23 ifmale, or 1.05 if female) x 1.73/BSA (m2)
Creatinine
Cystatin C formula by Hoek (201)
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GFR = (80.35/ Cystatin C concentration) - 4.32
For comparison, GFR was calculated GFR from two recently published equations:
The Mayo formula (20)
GFR = exp (1.911 + 5.249 / (creatinine x 0.0113) -2.114 / (creatinine x 0.0113)2-
0.00686 x age - 0.205 (iffemale)
The cystatin c equation by Grubb (204)
GFR=86.48 x cystatin c ~L686 x 0.948 (iffemale)
(iii) Blood spot iohexol clearance methods without haematocrit correction
In order to assess whether adjustment of the whole blood iohexol concentration in the
capillary blood spot for the measured venous blood haematocrit is necessary, a
haematocrit of 0.39 for women and 0.44 for men (the mean haematocrit in a large
community population based survey (30)) was substituted for the measured
haematocrit and the 3-spot, 2-spot and 4-hr-spot GFR estimates were re-calculated as
detailed above.
2.2.3.3 Statistical methods
Data analysis was undertaken at the Clinical Trial Service Unit, Oxford, UK. The
characteristics of routine referral patients and healthy volunteers were compared
using 2-sample t-tests for normally distributed variables, Wilcoxon rank-sum tests
for non-normally distributed variables and Pearson's chi-square test (with
appropriate continuity corrections) for dichotomous variables. Agreement of each of
the 6 test methods with the reference method was assessed by Bland-Altman plots of
the 'GFR difference' (test method GFR - reference method GFR) versus the mean of
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the reference method GFR and test method GFR (213). For each method the test
'bias' was defined as the mean of the GFR differences (so that a negative bias
corresponds to an underestimation of the GFR by the test method), and the test
'precision' was measured by the standard deviation of the GFR differences (i.e. a
smaller standard deviation indicates better precision); 95% limits of agreement were
defined as the bias ± 1.96 x precision. In order to allow comparisons of the overall
performance of each test method (including both components of bias and precision)
the mean squared error (MSE) was calculated as the variance of the GFR differences
plus the square of the bias. These analyses were repeated for all 3 blood spot iohexol
clearance methods calculated using a standard, rather than measured, haematocrit
and for the 2 spot and 1 spot methods using alternative sampling times (2 and 3 hours,
and 3 and 4 hours respectively).
In a secondary analysis, the performance of each test method in estimating GFR in
those with or without chronic kidney disease (CKD) was assessed. This involved
estimating the test bias and precision separately in those with a reference GFR <60
ml/min/1.73 m2 (the threshold level defined by the National Kidney Foundation for
the diagnosis of CKD (16)) and in those with a reference GFR >60 ml/min/1.73 m2.
In each group, the 'relative bias' (defined as the mean percentage difference between
the test and the reference estimates) was calculated and the differences were
compared using a 2-sample t-test.
In order to examine the potential influence on estimated GFR of inaccurate recording
of sample time, we performed a sensitivity analysis using simulation. This was done
by adding a normally distributed recall error (with mean zero and standard deviation
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ranging from 1 to 30 minutes) to the blood spot sample times, recalculating the
estimated GFR for each subject, and then recalculating the mean squared error of the
test. The above process was repeated 1000 times and, at each level of recall error,




The characteristics of the 81 participants are shown in table 2.1. The group of healthy
volunteers were younger and had lower median GFR (as estimated by the reference
method) than the routine referral patients.
2.3.2 Performance ofthe blood spot iohexol clearance methods
Table 2.2 shows the bias, precision and mean squared error of each of the test
methods: the Bland-Altman plots for each test method are shown in figure 2.1. The
3-spot (2, 3 and 4 hours), 2-spot (2 and 4 hours) and 1-spot (4 hours) capillary blood
spot iohexol clearance methods measured GFR with small biases, overestimating
GFR by only 1.1, 0.6 and 4.5 ml/min/ 1.73m respectively. The standard deviation of
the GFR differences for the blood spot iohexol clearance methods was similar for the
3-spot and 2-spot methods (7.7 and 7.6 ml/min/1.73m , respectively), and only
slightly greater for the 1-spot method (10.8 ml/min/1.73m2). Thus, the 95% limits of
agreement for the 3-spot and 2-spot methods were similar, while the limits for the 1-
spot method were slightly wider (Table 2.2 and Figure 2.1). The MSE (i.e. the
average squared difference between the test estimate and true reference level) of the
1-spot method was approximately twice that of the 2-spot or the 3-spot method
(Table 2.2).
2.3.3 Performance ofthe creatinine and cystatin c basedprediction equations
The MDRD, Cockcroft-Gault and cystatin c formulae all produced substantially
biased estimates ofGFR, underestimating GFR by an average of 15.7, 9.6 and 12.1
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ml/min/1.73m2 respectively (Table 2.2). While the standard deviations of the GFR
differences for these methods were similar (17.0, 16.8, and 16.2 ml/min/1.73m2
respectively), they were over twice that of the 3-spot method, resulting in much
wider 95% limits of agreement. All 3 of these prediction equations resulted in an
MSE more that 6 times that of the 3-spot method, with the MDRD formula
displaying the worst agreement with the reference method (an MSE nearly 9 times
that observed for the 3-spot method). For comparison, 2 recently published
prediction equations were also assessed. The 'Grubb' cystatin c formula (204), which
includes an adjustment for female sex, also resulted in a biased and imprecise GFR
estimate (bias ± 1.96 x SD: 10.7 ± 36.3 ml/min/1.73m2). However, the Mayo
creatinine equation (20), which includes a quadratic creatinine term, predicted GFR
with minimal bias, although the 95% limits of agreement were similar to the other
prediction equations (Bias ± 1.96 SD: 0.3 ± 30 ml/min/1.73m2).
2.3.4 Performance of test methods among those with and without CKD
While the performance of the 2-spot and 3-spot methods was similar among those
with a reference GFR >60 or < 60 ml/minl.73m2 (Table 2.3), the 1-spot method
• i *2overestimated GFR by 15.4% among those with GFR < 60 ml/mini.73m", compared
to only 4.8% among those with a reference GFR of > 60 ml/mini.73m2 (p=0.03,
Table 2.3). Among those with reference GFR <60 ml/min/1.73m2, the estimates
produced by the prediction equations (MDRD, Cockcroft-Gault, and cystatin C
formulae) showed little evidence of bias, and the precision was similar to that of the
blood spot methods (Table 2.3). However, these equations performed particularly
poorly among those with reference GFR >60 ml/min/1,73m2. The bias ± 1.96 x SD
was -25.3 ± 28.8 for the MDRD formula, -16.8 ± 32.6 for the Cockcroft-Gault
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formula and -19.5 ± 32.0 ml/min/1.73m2 for the cystatin C formula. Among those
with a GFR >60 ml/min/1,73m2 the MDRD, Cockcroft and Gault and cystatin C
formulae underestimated GFR by an average of 26.4%, 17.5% and 20.0%
respectively (p<0.005 for comparison with the relative bias of the same test method
among those with a reference GFR <60 ml/min/1.73m , Table 2.3).
2.3.5 Sensitivity analysis: Impact oferror in reported sample time
The influence of inaccurate recording of sample time on the expected mean squared
error of the 3 spot, 2 spot and 1 spot iohexol clearance test methods is shown in
Figure 2.2. All these methods were fairly robust to recall error, unless the standard
deviation of the sample time error exceeded 15 minutes. Since the sampling
distribution was Gaussian, this is approximately equivalent to the requirement that no
more that one third of subjects routinely misreport these times by 15 minutes or more.
Under this model, the 3-spot method lost its advantage over the 1-spot method once
the SD of the sample time error exceeded 30 minutes. This is because the 1-spot
method assumes a common gradient between dose and time and is thus less sensitive
to errors in the recording of the time of the blood sample.
2.3.6 Sensitivity analysis: Impact ofblood haematocrit measurement
When a standard haematocrit value (0.44 for men and 0.39 for women) was used in
place of the measured haematocrit, the 2-spot and 3-spot methods produced accurate
GFR estimates (Bias ± 1.96 SD: 0.2 ± 15.7 ml/min/1,73m2 and 0.7 ± 15.9
ml/min/1.73m respectively, Table 2.4). However, for the 1-spot method, the use of a
standard haematocrit value resulted in wide 95% limits of the agreement, and
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consequently large MSE (Bias ± 1.96 SD: 4.6 ± 32 ml/min/1.73m2, MSE 290.7,
Table 2.4).
2.3.7 Sensitivity analysis: Impact ofsampling time
The 1-spot method reported in the main analysis was based on a single blood spot
collected at 4 hours. The GFR estimates produced by the 1-spot method were less
accurate when a single blood spot collected at 2 or 3 hours was used (Bias ± 1.96 SD:
7.5 ± 30.6 ml/min/1.73m2 and 7.4 ± 20 ml/minl.74m2 respectively, Table 2.5).
Similarly, the 2-spot methods using blood spot samples taken at 2 and 3 hours, or 3
and 4 hours were substantially less precise (Bias ± 1.96 SD: -1.6 ± 38 and -4.9 ± 36.1
ml/min/1.73m2 respectively, table 2.5) than 2-spot method using blood sampled at 2
and 4 hours reported in the main analysis (Bias ± 1.96 SD: 0.6 ± 14.9).
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2.4 Discussion
This study has demonstrated that, as compared to iohexol clearance estimated from
venous samples taken at 2, 3 and 4 hours after iohexol injection, a novel method of
measurement of iohexol clearance using timed dried capillary blood spots can
estimate GFR with low bias and clinically acceptable precision. This study suggests
that 3-spot method provides little statistical advantage over the 2-spot method, but
that the 1 -spot method, although it measures GFR with low bias, may result in some
loss of precision.
This new method has two key potential advantages for large scale epidemiological
studies or trials compared to traditional iohexol clearance measured using timed
venous blood samples, or other exogenous tracer based methods of estimating GFR.
First, since iohexol in blood spots appears to be stable when sent through the mail
without refrigeration (211), GFR could be estimated in a multi-centre study without
the need for calibration of local laboratories or expensive transfer of venous samples
to a central laboratory. Second, following the iohexol injection, this method could
potentially be completed by the subject at home, which would reduce the time that
study participants would need to spend in clinics.
2.4.1 Performance ofthe creatinine and cystatin c basedprediction equations
In this study, the creatinine-based (MDRD (114) and Cockcroft-Gault (115)) and
cystatin-C-based (201) prediction equations performed poorly among individuals
without CKD (i.e. those with GFR > 60 ml/min/1.73m ). However, among patients
with established CKD (GFR < 60 ml/min/1.73m~) the performance of these
equations was comparable to the more direct methods. This suggests that the chief
54
advantage of the blood spot method is likely to be in clinical (and especially
epidemiological) studies requiring accurate measurement of GFR among individuals
without known CKD, in whom prediction equations are inadequate (20;21; 174).
In this sample, both the MDRD and the Cockcroft-Gault equations substantially
underestimated the reference GFR among those without CKD. When GFR is
estimated from serum creatinine concentration, the bias of the estimate is critically
dependent on the calibration of the creatinine assay (167). Recently, the MDRD
formula has been re-expressed for use with creatinine assays which are standardized
to an isotope dilution mass spectrometry (IDMS) reference method (214)
(section 1.3.1.3). In this study, we were unable to calibrate the creatinine assay,
either to the original MDRD laboratory method, or to an IDMS reference method.
Therefore, the extent to which the underestimation ofGFR by the MDRD equation in
this study is the result of differences in creatinine assay calibration is unknown. We
therefore compared our results with those from published studies assessing the
performance of an MDRD of the Cockcroft-Gault formula. In figure 2.3, the mean or
median reference GFR for each of the studies listed in tables 1.3 and 1.4 is plotted
against the reported bias (test method - reference method). There is a tendency for
these formulae, in particular the MDRD formulae, to systematically underestimate
GFR in populations with higher GFR levels. Using measurement of 125iothalamate
clearance in 580 healthy potential kidney donors and 320 patients with CKD at the
Mayo clinic in the US, Rule et al found that for a given blood creatinine
concentration, GFR was on average 26% higher in healthy individuals than in
patients with chronic kidney disease of the same age and sex (20). That study
developed a new prediction equation which included a quadratic creatinine term to
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account for this non-linear relationship between GFR and reciprocal creatinine
observed when the full population GFR range is considered (Table 1.2) (20). In our
data, this new 'Mayo' equation resulted in an unbiased estimate ofGFR; however the
imprecision of this formula was similar to the MDRD or Cockcroft-Gault formulae.
2.4.2 Performance ofblood spot iohexol clearance using earlier timepoints and
without measurement ofblood haematocrit
This study was able to further explore how blood spot iohexol clearance could be
used in a large scale epidemiological study by examining whether earlier time points
could be used without loss of accuracy, and whether measurement of haematocrit,
which would require either local measurement or refrigerated transport of blood
samples to the research laboratory, is necessary.
First, in the main analysis, the 2-spot method used samples taken at 2 and 4 hours
while the 1-spot method used only the 4 hour sample. The use of earlier time points
(2 and 3 hours for the 2-spot method, and 2 hours for the 1-spot method) might be
more convenient for participants and research staff. However, both the 1-spot and 2-
spot methods were substantially less accurate when these earlier time points were
used (Table 2.5).
Second, substituting the mean haematocrit values for men and women from a
population survey (30) in place ofmeasured haematocrit did not affect the
performance of the 2-spot or 3-spot iohexol method, but led to a loss of precision in
the 1-spot method.
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2.4.3 Limitations ofthe study
First, the blood spot sampling was performed by study staff. For large scale studies,
one of the key advantages of this method compared to existing exogenous tracer
based GFR methods is the potential for the blood spots to be collected by the
participants themselves at home. However, further research is needed to establish
whether subjects would themselves be able to take adequate blood spot samples after
a short training within a study clinic appointment.
Second, the precise sample time was recorded by the researcher in this study. If the
samples were collected by participants at home, misreporting of the blood spot
sample collection could affect test accuracy. We were able to simulate the potential
impact ofmisreporting of sample time on test performance by adding a randomly
distributed error variable to the recorded time in our data. This showed that, even if a
third of patients misreported the times with an error of 15 minutes, there would be
little reduction of the accuracy of the 3 spot, 2 spot or 1 spot methods (Figure 2.2).
Third, estimation ofGFR from the clearance of iohexol from the blood measured
using 3 timed venous samples was used as the reference method in this study rather
than inulin or 51Cr-EDTA clearance. The choice of reference method was pragmatic
and the clearance of a single bolus of iohexol has been shown in previous studies to
be equivalent to the gold standard methods of inulin (90;215) and 51Cr-EDTA
clearance (89; 178).
Fourth, because of the reference method used, this study is not able to reliably assess
whether the blood spot iohexol clearance method, or the formulae estimating GFR
from blood concentration of creatinine or cystatin c, can accurately estimate true
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GFR among individuals with stage 4 or 5 CKD (GFR < 30 ml/min/1.73m2 (16)).
Among such individuals, plasma iohexol clearance measured using a late plasma
sample, usually taken around 24 hours after the iohexol injection, better reflects renal
iohexol clearance than the reference method used in this study (216). Modification of
the blood spot method to include a late sampling point and further validation would
be required before using this method among individuals with stage 4 or 5 CKD.
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2.5 Summary of key findings
■ Blood spot iohexol clearance measured using 3 dried capillary blood spot
samples taken at 2, 3 and 4 hours following an iohexol injection accurately
measured GFR among individuals with a wide range ofGFR values.
■ Using 2 blood spots sampled at 2 and 4 hours resulted in similar accuracy to the 3
spot method.
■ Using a single blood spot collected at 4 hours resulted in some loss of precision
and, among those with GFR <60 mlmin/1.73m2, led to an overestimation ofGFR.
■ Among those with GFR >60 ml/min/1,73m2 the MDRD, Cockroft-Gault and
cystatin C formulae substantially underestimate GFR and produce an imprecise
estimate for an individual.
■ The 1 spot method using earlier sampling times (2 or 3 hours rather than 4 hours)
resulted in greater bias and less precision.
■ The 2-spot method was substantially less accurate when the sampling times were
close together (2 and 3, or 3 and 4 hours, rather than 2 and 4 hours).
■ Measurement of individual blood haematocrit values is not necessary when the 2-
or 3-spot methods are used.
■ The accuracy of all 3 blood spot methods was not substantially affected by a
simulated scenario in which the sampling time was misreported by more than 15
minutes in approximately 1 /3rd of participants.
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Table 2.2: Agreement of each test method with the reference method of iohexol
clearance measured in three venous samples.




3 spot iohexol clearance 1.1 7.7 -13.9 to 16.2 60.0
2 spot iohexol clearance 0.6 7.6 -14.3 to 15.5 58.2
1 spot iohexol clearance 4.5 10.8 -16.8 to 25.7 137.3
Prediction equations:
MDRD formula -15.7 17.0 -49.1 to 17.6 536.6
C&G formula -9.6 16.8 -42.5 to 23.2 374.1
Cystatin C formula -12.1 16.2 -43.7 to 19.6 406.7
Values are given in ml/min/1.73nr
Bias = Mean (test method GFR - reference method GFR), SD = Standard deviation (test method GFR
- reference method GFR), Limits of agreement = Bias±1.96 x SD, MSE = Mean squared error, MDRD
= Modification of Diet in Renal Disease study (114), C&G = Cockcroft and Gault (115)
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Table 2.4: Agreement of the Blood Spot Iohexol Clearance (BSIC), without measured
haematocrit, with the reference method of iohexol clearance measured in three venous
samples.
Blood spot methods Bias SD Limits of MSE
agreement
3 spot lohexol clearance 0.7 8.1 -15.2 to 16.5 65.8
2 spot iohexol clearance 0.2 8.0 -15.5 to 15.8 63.8
1 spot iohexol clearance 4.6 16.4 -27.5 to 36.8 290.7
Bias = Mean (test method GFR - reference method GFR), SD = Standard Deviation (test method GFR -
reference method GFR), Limits of agreement = Bias±1.96 x SD, MSE = Mean Squared Error
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Table 2.5: Agreement of Blood Spot Iohexol Clearance (BSIC), measured using
alternative sampling times, with the reference method of iohexol clearance measured
using 3 venous samples
BSIC methods Bias SD Limits of MSE
agreement
1-Spot method using different sampling times:
2 hour 7.5 15.6 -23.2 to 38.1 299.7
3 hour 7.4 10.2 -12.6 to 27.4 171.4
4 hour (as used in main analysis) 4.5 10.8 -16.8 to 25.7 137.3
2-Spot method using different sampling times:
2 and 3 hours -1.6 19.3 -36.3 to 36.3 376.3
3 and 4 hours -4.9 18.4 -40.9 to 31.0 360.9
2 and 4 hours (as used in main analysis) C6 7.6 -14.3 to 15.5 58.2
Values are given in ml/min/1.73m2
Bias = Mean (test method GFR - reference method GFR), SD = Standard Deviation (test method
GFR - reference method GFR), Limits of agreement = Bias±1.96 x SD, MSE = Mean Squared
Error
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Figure 2.1: Bland and Altman plots showing agreement of (i) 3-spot iohexol clearance,
(ii) 2-spot iohexol clearance, (iii) 1-spot iohexol clearance, (iv) the MDRD formula (114),
(v) the Cockcroft-Gault formula (115) and (vi) the Cystatin C formula (201) with the
reference method of iohexol clearance measured in three venous samples.
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Mean of test and reference method
For each individual the 'GFR difference' (test method GFR - reference method GFR) on the y axis is plotted against
the 'mean GFR' (mean of the reference and test methods). The bias (calculated as the mean GFR difference) is shown
by the dashed line. The upper and lower 95% limits of the agreement [bias±l .96 x SD] are indicated by the upper and
lower dotted lines.
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Figure 2.2: The effect of adding of random error to the recorded blood spot sample time
on the accuracy of the 3 spot, 2 spot and 1 spot iohexol clearance methods.
— 1 spot iohexol clearance
2 spot iohexol clearance
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To simulate the effect of error in recording sample time, random error from a normal distribution with a
mean of zero minutes and a Standard Deviation (SD) of x minutes (with x allowed to vary from 0-30
minutes) was added to each of the 3 recorded blood spot sample times for all 81 participants and GFR
recalculated using the 3 spot, 2 spot and 1 spot test methods for each individual. The Mean Squared Error
(MSE) of each recalculated test method was then calculated for the study population. This process was
repeated 1000 times and the mean MSE over the 1000 repetitions was calculated.
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Figure 2.3: Reported bias in studies assessing the performance of the Modification of




















Mean/median reference GFR (ml/min/1,73m )
For each of the studies listed in table 1.3 and 1.4 the reported bias [mean (test method GFR - reference
Method GFR)] of the Cockcroft and Gault (115) and/or an MDRD formulae (114; 116), are plotted against
the mean or median reference GFR of the study population. One study (194), published only in abstract, is
not included as it did not provide the reference GFR of the study population.
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3.1 Aims of the study
In Chapter 2, GFR measured by a novel method in which iohexol clearance is assessed
using dried capillary blood samples (blood spot iohexol clearance or 'BSIC') showed
good agreement with traditional iohexol clearance measured using 3 timed venous blood
samples. However, in that study, and in other published studies which have used dried
capillary blood spot samples (217-219), the blood spot samples were collected by trained
staff. One of the principal advantages of this method for epidemiological studies,
however, is the potential for the blood sample collection to be undertaken by the
participants at home after the clinic.
This study aimed to assess the feasibility, including acceptability to patients, of using the
BSIC method, in which the blood sampling is completed by participants themselves after
the clinic. In particular, the study aimed to address the following methodological issues;
• the feasibility of teaching participants to take capillary blood spot samples within a
single clinic visit,
• the ability of participants to collect and return 2 timed blood spot samples to the
clinic, and to record the sample collection time, and
• the size and quality of samples returned by participants.
The study was conducted in compliance with the Declaration ofHelsinki and approval




This study aimed to recruit a wide range of individuals to enable the assessment of the
feasibility of the blood spot iohexol method in men and women, across a wide range of
age groups, and among healthy individuals as well as those with prior disease.
Participants were recruited from the following sources;
■ Relatives of outpatients followed up at the Oxford Kidney Unit,
■ Participants in the Study of the Effectiveness ofAdditional Reductions in Cholesterol
and Homocysteine (SEARCH) and their relatives,
■ Clinical Trial Service Unit staff and other members of the University of Oxford
Details of the recruitment methods for the different participant sources are described
below:
3.2.1.1 Relatives of outpatients followed up at the Oxford Kidney Unit
A few weeks before their next scheduled outpatient appointment, patients attending the
Oxford Kidney Unit outpatient department were sent a letter asking them give an
invitation letter and participant information sheet to any family member or friend who be
accompanying them to their outpatient appointment, and complete and return a reply slip.
On the reply slip the Oxford Kidney Unit patient was asked to indicate one of the
following responses;
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■ "My family member is interested in taking part in this study. Please contact them at
the address below to arrange an appointment"
■ "I attend the Oxford Kidney Unit outpatient department with a member ofmy family
but they are not interested in taking part in this study"
■ "This invitation is not relevant to me because I attend the Oxford Kidney Outpatient
Department without a member ofmy family"
3.2.1.2 Participants in the SEARCH study and their relatives
Approximately 260 of the 12,000 SEARCH participants were enrolled at the Oxford site.
By December 2004, around 240 individuals were attending 6 monthly follow-up at the
Clinical Trial Service Unit. A few weeks before their next scheduled follow-up
appointment, these participants were sent a letter inviting them, and/or a family member
or friend who would be accompanying them to the clinic, to participate in this study on
the same day as their SEARCH appointment. The SEARCH participant was asked to
complete a reply slip indicating one of the following responses;
■ "I am interested in taking part in this study. Please contact me to arrange an
appointment"
■ "I am not interested in taking part in this study"
3.2.1.3 Clinical Trial Service Unit staff and other members of the University ofOxford
Approximately 180 individuals work within the Clinical Trial Service Unit.
Approximately a further 150 individuals work in other University Departments on the
same site (the National Perinatal Epidemiology Unit, the Cancer Epidemiology Unit and
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the Division of Public Health and Primary Health Care). An invitation letter was sent to
every member of staff in the 4 units requesting volunteers for this study.
3.2.2 Eligibility
Inclusion criteria;
Men and women aged >18 years
Exclusion criteria;
■ History of chronic kidney disease requiring renal replacement therapy
■ History ofmultiple myeloma, sickle cell disease or uncontrolled thyroid disease
■ Acute illness requiring hospital admission within the last month
■ Known hypersensitivity to radiographic contrast media
■ Childbearing potential
" Life-threatening illness (e.g. cancer)
Myeloma, sickle cell disease and uncontrolled thyroid disease are relative
contraindications to the use of iohexol (93) and the safety of iohexol has not been
established in pregnancy.
3.2.3 Clinic visit
Participants attended a single clinic which included the following;





■ Laboratory sample collection including the collection of dried capillary blood spots
after the clinic
Clinic study visits were conducted by trained personnel (Research Fellow [MM] or
Study Research Nurse) and data were collected using a standard case report form. Each
participant was allocated a unique 4 digit study ID.
3.2.3.1 Assessment of eligibility
Identifying data (Title, Name, Date of Birth, Sex, Address, General Practitioner, unique
study ID) and recruitment source (University staff, SEARCH study, Oxford Kidney Unit,
Other) were recorded. Each exclusion criteria was discussed with the participant.
Childbearing potential (women in whom current pregnancy was a possibility) was
determined by the participants themselves. Participants with a permanent pacemaker in
situ could take part in the study but did not have the bioimpedance measurement.
3.2.3.2 Informed consent
Following a full explanation of the study, patients were asked to provide written
informed consent for the study procedures. In addition, participants provided consent for
the long term storage of blood and urine sample for use in future medical research.
3.2.3.3 Medical history
Study staff specifically asked about the following conditions;
(i) Chronic Kidney Disease
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Chronic Kidney Disease was considered to be present if the patient reported a history of
"kidney damage" or "kidney disease".
(ii) Angina (stable or unstable)
Angina was considered to be present if the participant reported a diagnosis of angina, a
history of exertional chest pain or had been admitted to hospital with chest pain without
other cause.
(iii) Myocardial infarction (MI)
A history ofMI was self reported by participants.
(iv) Coronary revascularisation
A history of coronary revascularisation was considered present if the participant reported
a history of coronary artery bypass surgery or coronary angioplasty with or without
stenting.
(v) Non-coronary revascularisation
A history of non-coronary revascularisation was considered to be present if the
participant reported a history of non-coronary angioplasty or arterial revascularisation
surgery (carotid endarterectomy, abdominal aneurysm repair or peripheral arterial
bypass surgery)
(vi) Peripheral Vascular disease (PVD)




A history of stoke was considered present if the participant reported a physician
diagnosis of stroke or a history of sudden onset neurological deficit lasting > 24 hours.
(viii) Diabetes Mellitus
A history of diabetes mellitus was considered to be present if the participant was
receiving treatment for diabetes or reported a physician diagnosis of diabetes.
(ix) Treated hypertension
A history of treated hypertension was considered to be present if participants reported
taking antihypertensive treatment without other indication.
(x) Smoking status
Participants were recorded as current smokers (if they continued to smoke or had
stopped smoking in the last month) or ex-smokers.
3.2.3.4 Ethnic origin
Participants were asked to classify themselves as one of the following;
■ White






A complete list of the participant's current medication (without dose information) was
recorded.
3.2.3.6 Clinical measurements
After removing footwear, height was measured to the nearest 0.5 cm using a wall
mounted chart. Weight was measured to the nearest 0.1cm using a Tanita Body
Composition Analyser (TBF-300, TANITA UK Ltd, Middlesex, UK) after removing
shoes and heavy garments. After removal of outer clothing the natural waist was
measured to the nearest cm. Blood pressure was measured once while seated using a
British Hypertension Society approved digital sphygmomanometer (Model UA-767,
A&D Instruments Ltd, Oxfordshire, UK). Provided the participant does not have
permanent pacemaker in, an assessment of body composition was made by measurement
of single frequency bioimpedance using a Tanita Body Composition Analyser (TBF-300,
TANITA UK Ltd, Middlesex, UK). After voiding, outer garments, pocket contents,
metal jewellery, shoes and socks were removed. The participant was then asked to step
onto the analyser with one foot on each foot plate and a single measurement was made
in which the analyser passes a 50Hz current though the lower limbs. The TANITA TBF-
300 analyser reports the following parameters;
■ measured impedance (in ohms),
" total body water (calculated according to the manufacturers prediction equations from
weight, age and height /imdedance),
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■ fat free mass (FFM) (based on the manufacturers assumption that 73.2% of FFM is
water), and
■ percentage body fat ([weight-FFM]/weight).
3.2.3.7 Blood spot blood sample collection and administration of iohexol
The participant was trained and observed taking 'finger prick' capillary blood spots
using a 'Unistik 2 normal' disposable lancet (Owen Mumford, Oxford, UK), applying
pressure to the proximal finger and dropping two capillary blood spots onto the blood
collection card (Schleicher and Schuell Grade 903, Dassel, Germany) from a single
'finger prick'. The blood spots had to be at least 7mm in diameter. The participant was
instructed not to 'smudge' the spot, by touching the card with the finger, or to 'layer' the
spot, by dropping several spots on the same area of the card. If sufficient spots could not
be obtained, then a 'Unistik 2 super' disposable lancet (Owen Mumford, Oxford, UK)
was used.
An intravenous cannula was then inserted, venous blood samples drawn (9ml EDTA and
5ml Sodium Fluoride EDTA) and an intravenous bolus of 5ml (300mg/ml) iohexol was
administered. The participant was then given a blood spot sampling kit (which includes
written instructions, a blood spot card labelled with their study ID, three disposable
lancets, cotton wool, 2 re-sealable plastic bags and a re-sealable SHARPS disposal
container). The participant was asked to undertake further capillary blood sampling at
approximately 2 and 4 hours after the iohexol injection. From each 'finger prick' two
capillary blood spots were to be collected and the precise time (to the nearest minute)
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recorded on blood spot card. Participants were instructed to allow the blood spot
samples to dry for 30 minutes before placing each completed blood spot card in a sealed
plastic bag. The participant was asked to return the dried capillary blood spots to the
clinic, along with a completed questionnaire, by post using the envelope provided. The
participant was observed for 15 minutes after the administration of iohexol before
leaving the clinic.
3.2.3.8 Participant questionnaire
After completing the blood spot sample collection after the clinic, participants filled in a
short questionnaire in which they selected the most appropriate answer to the following
questions:

























The questionnaire was then returned to the clinic along with the dried capillary blood
spots.
3.2.3.9 Sample storage and laboratory methods
Venous blood samples were stored at -4°C until transfer to the laboratory. Whole blood
removed from the EDTA blood sample was analysed for haematocrit and haemoglobin
(GEN-S, Beckman Coulter, Bucks, UK). Eighty eight percent of samples were processed
on the same day as collection with the remaining samples processed the following day.
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Completed blood spot collection cards were returned to the study clinic by first class
post. A photocopy of each card was made in order to store the recorded the blood spot
sample time and provide a record of sample quality. The samples were the stored at -
80°C. The blood spot samples were then transferred in batches to the South West
Thames Institute of Renal Research by courier at room temperature. The methods used
to analyse blood iohexol concentration in dried capillary blood spots, and the
calculations used to estimate GFR corrected for body surface area from 2 blood spots are
outlined in section 2.2.3.1. For comparison, GFR was also estimated from blood
creatinine concentration by the abbreviated MDRD formula (114) and from blood
cystatin c concentration according to the published formula by Hoek et al (201)
described in section 2.2.3.2
3.2.3.10 Data entry and storage
Data collected in the clinic, the results of the questionnaire and the blood spot collection
times recorded by the participants were manually entered onto a spreadsheet (Microsoft
Exel® 2002) by one investigator [MM]. Each row of data was checked by the same
investigator on a separate day.
The concentration of iohexol in the blood spots was analysed in the South West Thames
Institute of Renal Research, St Helier Hospital and the results were recorded on a
separate spread sheet (Microsoft Exel® 2002). The quality of the blood spots was
subjectively assessed by a Consultant Biochemist at the South West Thames Institute of
Renal Research, St Helier Hospital (JB). Spots which were too small to allow
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quantification of the iohexol concentration were considered 'inadequate'. Blood spots
which were analysable for iohexol concentration but were either small, or showed
'multiple spotting' (several blood spots applied to the same area) or 'smudging' (direct
contact between the filter paper and the finger) were considered 'poor quality' (Figure
3.1). The results of the laboratory tests measured in the venous baseline blood sample
were exported from the Clinical Trial Service Unit Laboratory Information Management
System (LIMS) as a spreadsheet (Microsoft Excel® 2002). Data was stored in central
Clinical Trial Service Unit server.
3.2.4 Statistical methods
Data were expressed as mean ± standard deviation and range for continuous data and as
percentage for categorical data. The results of the study questionnaire were displayed as
a pie chart (Microsoft Excel® 2002). Possible 'rounding up' of reported sampling time
was explored by analysis of digit preference. The proportion of recorded times in which
the last digit was "0" was compared with the expected frequency of 10% using a chi
squared test (Microsoft Excel® 2002) (220). The distributions of GFR measured by
blood spot iohexol clearance (BSIC-GFR) and GFR estimated from blood
concentrations of creatinine (MDRD-GFR) and cystatin c (cyc-GFR) (restricted to
individuals who returned 2 analysable blood spot iohexol samples and had
measurements of blood creatinine and cystatin c concentrations (n=106)) were displayed
as box and whisker plots showing the median, interquartile and 95% range (Stata v8.2
(StataCorp, Texas, USA)).Participants were considered to have a 'high GFR' if the
BSIC-GFR value was above 133 ml/min/1.73m2 (the 95th centile ofmeasured iohexol
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clearance among 365 healthy potential donors (173)) and were considered to have a 'low
GFR' if the BSIC-GFR value was below 70 ml/min/1.73m2 (the 5th centile of GFR from
the same population (173)). The characteristics of those with a 'high GFR' and a Tow
GFR' were compared to those with a 'normal GFR' using a chi squared test for




3.3.1 Participant recruitment and characteristics
Of the 111 eligible participants, 53 were recruited through the SEARCH clinic, 43 from
University Staff and 15 through the Oxford Kidney Unit. Around 28% of invited
SEARCH participants took part (Figure 3.2). Approximately 13% of staff at the Clinical
Trial Service Unit, National Perinatal Epidemiology Unit, Cancer Epidemiology Unit
and Department of Public Health and Primary Care volunteered for the study. Around
9% of invitations sent to Oxford Kidney Unit patients resulted in a family member
volunteering for the study (Figure 3.2) although the number of Oxford Kidney Unit
patients who attended the outpatient department with a family member is not known.
The characteristics of the 111 eligible participants are shown in table 3.1.
3.3.2 Quality ofreturnedfinger-prick blood samples
All 111 participants successfully collected baseline finger-prick blood samples in the
clinic. One hundred and eight participants (97.3%) returned blood spot samples from
both time points. Two further participants returned only a single sample (Figure 3.3).
Of the 108 participants who returned 2 samples, only 1 returned a sample which was too
small to allow quantification of the iohexol concentration. However, 24 participants
returned samples which, while they were analysable, were either small or had been
collected using 'poor' technique, e.g. 'smudging' (touching the blood spot collection
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card with the finger) or 'multiple spotting' (the application of several spots to the sample
area of card) (Figure 3.1).
3.3.3 Recording ofsample time by participants
The sample time was recorded clearly and legibly on all 218 returned blood sample
cards. Among the 108 participants who returned samples from both time points, the
recorded sample times for the first (2 hour) sample ranged from 108 minutes to 192
minutes after the iohexol injection, with a mean (±standard deviation) recorded time
interval of 125±10 minutes. The recorded sample times for the second (4 hour) sample
ranged from 193 minutes to 318 minutes after the iohexol injection, with a mean
(±standard deviation) recorded time interval of245±14 minutes. Among those who
returned 2 samples, 94% of the recorded 2 hour sample times and 91% of the recorded 4
hour sample times were within 15 minutes of the scheduled sampling time. In all 218
returned samples, examination of the frequency of the last digit used in recording the
sample time demonstrated a preference for the digit "0" which was recorded as the last
digit in 22% of time records compared to the expected 10% (Chi2 25.1, p<0.0001)
(Figure 3.4).
3.3.4 Acceptability questionnaire results
One hundred and eight participants returned a completed acceptability questionnaire.
Ninety four percent of those who returned the questionnaire found the iohexol injection
in the clinic to be either "acceptable" or "very acceptable" (Figure 3.5a) and 90% of
responders found taking the blood sample after the clinic using the finger-prick method
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to be either "acceptable" or "very acceptable" (Figure 3.5b). When asked in detail, 90%
of respondents found actually pricking the finger "easy" or "very easy" (Figure 3.6a) but
only 72% found dropping the blood spot onto the filter paper "easy" or "very easy"
(Figure 3.6b).
3.3.5 Measured GFR
The mean (±standard deviation) GFR measured using blood spot iohexol clearance
(BSIC-GFR) was 103.1 (±28.3) ml/min/1.73m2, significantly higher than that estimated
by the MDRD formula (MDRD-GFR) and estimated from the blood concentration of
cystatin c (cyc-GFR) (90.5 (±18.1) and 92.0 (±19.3) ml/min/1.73m2 respectively)
(p<0.001 for each compared to BSIC-GFR) (Figure 3.7). In addition, the distribution of
BSIC-GFR values was wider than that of the MDRD-GFR or the cyc-GFR with some
individuals having very high BSIC-GFR values (Figure 3.7). The characteristics of
participants with a "high" and "low" BSIC-GFR (defined as above the 95th centile or
below the 5th centile of GFR measured by 125iothalamate clearance among 365 healthy
potential kidney donors (173)) are shown in table 3.2. As expected, participants with a
"low" BSIC-GFR were older (mean±standard deviation age 67.7±9.8 compared to
52.4±13.5 among those with "normal" BSIC-GFR [p<0.001 ]) and more likely to have
cardiovascular disease (77% compared to 29% among those with "normal" BSIC-GFR
[p<0.001]) (Table 3.2). Surprisingly, the mean age among those with a "high" BSIC-
GFR and those with a "normal" BSIC-GFR was similar (51.4± 16.2 and 52.4±13.5
respectively [0=0.794]), as was the proportion of individuals with cardiovascular disease
(38% and 29% respectively [p=0.479]).
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3.4 Discussion
3.4.1 Potential advantages of the BSIC methodfor use in epidemiological studies
In epidemiological studies, the use of dried capillary blood spots has important practical
and economic advantages over venous blood samples; avoiding the need for trained
phlebotomists, venepuncture equipment, refrigeration of samples and early laboratory
processing (217). In the measurement of GFR, the use of these samples has the
additional advantage that the collection of the timed blood samples could potentially be
completed by the subjects themselves, substantially reducing the amount of time spent in
the clinic.
In this study, a wide range of individuals were trained to take capillary blood samples
during a single clinic visit, and all but 1 participant returned at least one dried capillary
blood sample through the post. Both the injection of iohexol in the clinic and the finger-
prick blood sample collection after the clinic were acceptable to > 90% of participants.
3.4.2 Methodological issues raised by this study
This study assesses two importance methodological issues in the development of the
BSIC technique; the quality of samples collected by study participants at home and the
accuracy of the recorded sample time.
The quality of the dried capillary blood spot samples may be important in determining
the accuracy of the BSIC method. In order to estimate the concentration of any
substance in a dried capillary blood spot, it is necessary to know the volume of blood
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contained within the bloods spot sample. The method used in this study, as in other dried
blood spot assays (221-224), makes use of the properties of the filter paper, which,
provided the sample is collected using proper technique (a single drop of blood allowed
to diffuse into the card by capillary action), can be assumed to contain an approximate
volume of blood within a standard punch of the dried filter paper blood spot. The sample
absorption properties of the filter papers are standardized under United States (US) Food
and Drug Administration regulations and are subjected to a rigorous quality-control
program by the US Newborn Screening Quality Assurance Program (218). However, the
volume of blood contained in the standard punch is influenced by the blood haematocrit
(225), the amount of blood dropped onto the card (218) and whether the punch is taken
from the centre or the periphery of the blood spot (218). Layering of blood spots, when
more than one spot applied to the same area of the card, and smudging of the blood onto
the card with the finger could have substantial effects on the volume of blood contained
in a standard punch. In this study, just less than one quarter of participants returned a
blood spot at one or more time point which was judged to be 'poor quality'. This
suggests that analysis of iohexol concentration in dried capillary blood spots collected
by participants themselves using the current laboratory method may be not be accurate.
Direct estimation of the volume of blood contained within a whole dried blood spot
might enable more accurate measurement of iohexol concentration in poor quality blood
samples for 2 reasons; First, it would not be necessary to rely on the assumed
relationship between the area of the filter paper and the volume of blood contained
within that area, which may not be valid in poor quality spots. Second, it would increase
the total amount of sample which can be analysed, since it would not be necessary to
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discard the 'un-punched' area. Such methods might include the simultaneous
measurement of the quantity of a 'volume marker' (e.g. haemoglobin or sodium (225))
in the dried blood spot, measurement of the concentration of the same 'volume marker'
in the baseline venous blood sample and, assuming that the concentration of the 'volume
marker' in venous and capillary blood is the same, the volume of blood in the spot
required could then be calculated. This study suggests that such advances in laboratory
technique may be necessary to accurately measure the concentration of iohexol (and
other parameters) in dried blood spots collected by study participants themselves.
The test accuracy could be affected by inaccuracies in the sampling time in 3 ways: The
samples could be taken outside the scheduled time but the actual sampling time recorded
accurately, the samples could be taken at the scheduled time but the sampling time
recorded inaccurately, or the both errors could occur.
First, substantial deviation from the requested sampling time might reduce test accuracy
even if the sampling time is recorded accurately. When blood spots samples are
collected by laboratory staff, iohexol clearance measured using 2 dried capillary blood
spots taken at 3 and 4 hours, or 2 and 3 hours after the iohexol injection is less accurate
than that measured using samples taken at 2 and 4 hours (Section 2.3.7). In this study,
the self recorded sampling time was within 15 minutes of the scheduled 2 and 4 hour
sampling times in > 90% of the 108 participants who returned both samples.
Second, inaccurate recording of sampling time could reduce the accuracy of the blood
spot iohexol clearance measurement. In this study, the true sample time was not known
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and therefore the error in recording of the sample time cannot be assessed directly.
However, this could be explored by examination of digit preference. Analysis of digit
preference has suggested a tendency to 'round up' numeric data in a range of research
settings, including the recording of blood pressure (226), self reported number of
cigarette smoked per day (227) and in recorded attendance times in accident and
emergency departments (228). In this study, analysis of the terminal digit of self
reported sampling time demonstrated a preference for the digit "0" suggesting that the
sample time was not accurately recorded in at least some participants. In chapter 2,
modeling the impact of error in recorded sample time previously suggested that a
scenario in which approximately a third of individuals recorded the sample time with an
error of at least 15 minutes would have only a small effect on the accuracy of the BSIC
method. However, there is some evidence that this apparent "rounding-up" of the
sampling time may reflect more substantial inaccuracy in some participants. The finding
that 15% of individuals in this study had a BSIC-GFR value above the 95th centile of
1 9S
GFR measured by iothalamate among 365 healthy potential kidney donors (mean age
41.1 years) is surprising since our study popululation is older (mean age 54.3 years) and
38% of participants had cardiovascular disease. In addition, those individuals with
"high" BSIC-GFR values (those above the 95lh centile of GFR among potential kidney
donors) were not younger or less likely to have cardiovascular disease than those with a
"normal" BSIC-GFR (those between the 5th and 95th centile of GFR among potential
kidney donors). These findings suggest that some individuals might have forgotten to
take one or more of the blood spot samples until after the scheduled time and then
"made up" a sampling time near to the scheduled time resulting in artificially high
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iohexol celarance values. The impact of this sort of error on test accuracy would be
substantial. Providing participants with an automated time recording device must be
considered for future studies.
3.4.3 Weaknesses ofthis study
Two weaknesses of this study should be considered. First, the study population was not
a random sample of the local population. In addition, the reasons for not volunteering,
which may include finding the idea of the BSIC procedure unacceptable, are not known.
The recruitment methods were selected for pragmatic reasons and did ensure that the
study population, the majority of which were not University Staff, included men and
women across a wide range of age groups. Since the ages of the participants ranged from
24-77 years, these results may not be representative of the feasibility of undertaking this
procedure in the elderly.
Second, since a reference GFR was not measured, the accuracy of the blood spot iohexol
method in this setting cannot be directly assessed. Simultaneous measurement of a
reference method using timed venous blood samples would invalidate the attempt to
assess the feasibility of conducting the procedure outside the clinic environment.
Subsequent measurement of a reference method GFR would have substantially increased
the resources required for the study, both in cost and staff time and would have required
an additional visit to the clinic for the participants. The aim of this study was to assess
the feasibility of measuring blood spot iohexol clearance from samples collected by
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participants themselves after the clinic to inform further method development. Further
validation of the method would be required prior to use in an epidemiological study.
3.5 Summary of key findings
■ Measurement of Blood Spot Iohexol Clearance (BSIC) using timed finger-prick blood
samples collected after the clinic is acceptable to a wide range of individuals.
■ The BSIC method is potentially feasible for use in large scale epidemiological studies,
but laboratory techniques must be improved to make use of small and 'poor quality'
blood spots.
■ When the timed capillary blood sampling is completed by participants at home, the
self reporting sampling time may be inaccurately reported. This study also suggests
that in some participants there may be large discrepancies between the recorded and
actual sampling times resulting in reduced test accuracy. Future studies should
provide participants with an alarm and timing device.
■ In view of the methodological issues raised by this study, further development and













n 43 53 15 111
Age 41.4±8.8 67.4±8.6 58.1±14.0 54.8±14.4
(25-58) (40-77) (40-76) (24-77)
Female
56% 34% 60% 46%
Prior CVD 0% 75% 13% 38%
Diabetes 0% 8% 0% 4%
Hypertension 5% 28% 20% 18%
Current smokers 2% 8% 13% 6%
Ex-smokers 24% 62% 20% 42%
SEARCH, Study of the Effectiveness ofAdditional Reductions in Cholesterol and
Homocysteine; CVD, cardiovascular disease (defined as a self reported history of angina,
myocardial infarction, coronary or non-coronary revascularisation, stroke or peripheral
vascular disease).
Data are given as mean ± standard deviation (range) or percentage
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Table 3.2: Characteristics of participants with a "high", "low" and "normal" GFR
measured by blood spot iohexol clearance
BSIC GFR (ml/min/1.73m2) low p* normal high P**
<70 70-133 >133
n 13 77 16
BSIC GFR (ml/min/1,73m2) 58.3±12.1 p<0.001 100.9±15.0 151.1±13.8 p<0.001
MDRD GFR (ml/min/1.73m2) 67.0±13.5 p<0.001 92.2±16.3 101.7±13.0 p=0.030
Cystatin C GFR (ml/min/1.73m2) 65.0±12.8 p<0.001 93.4±16.1 107.8±15.8 p=0.002
Age (years) 67.7±9.8 p<0.001 52.4±13.5 51.4±16.2 p=0.794
Female 4(31%) p=0.247 37 (48%) 9 (56%) p=0.551
Prior CVD 10(77%) p=0.001 22 (29%) 6 (38%) p=0.479
Hypertension 5 (38%) p=0.035 11 (14%) 3 (18%) p=0.650
Data are shown as mean ± standard deviation or number (percentage). The cut points used to define a
"low" and "high" GFR represent the 5th and 95th centile of GFR measured by l25iothalamate clearance
among 365 healthy potential kidney donors (173). Analysis is restricted to individuals who returned 2
analysable blood spot iohexol samples and had measurements of blood creatinine and cystatin c
concentrations (n=106).
* Proportion or mean among those with "low" GFR compared to "normal" GFR compared using a chi
squared test or 2 sample t-test respectively
**Proportion or mean among those with "high" GFR compared to "normal" GFR compared using a chi
squared test or 2 sample t-test respectively
BSIC, blood spot iohexol clearance; MDRD, modification of diet in renal disease study; CVD,
cardiovascular disease
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Figure 3.1: Example blood spots
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Figure 3.2: Recruitment of participants
a. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
(SEARCH)
b. Oxford Kidney Unit (OKU)
* 1 did not take part for administrative reasons
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Figure 3.3: Number and quality of returned blood spot samples
A blood spot sample was considered 'inadequate' if no quantification of the
concentration of iohexol was possible. A blood spot sample was considered 'poor
quality' if there was evidence of poor collection technique (section 3.3.2).
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Figure 3.4: Frequency of the last digit used in the recorded blood spot sample time
Last digit in recorded sample time
2
(p<0.0001, Chi comparison with an expected 10% frequency of each digit)
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Figure 3.5: Acceptability of the finger-prick blood sample collection procedure to
participants









b. "Overall, I found taking the finger prick blood spots to be:'
Data displayed as the proportion of respondents (n=108) who selected each answer on the questionnaire
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Figure 3.6: Participants assessment of the finger-prick blood collection procedure
















Data displayed as the proportion of respondents (n=108) who selected each answer on the questionnaire
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Figure 3.7: Box and whisker plots showing the distributions of glomerular filtration rate
measured by blood spot iohexol clearance and estimated from blood creatinine and
cystatin c concentrations
The central white lines indicate the median value, the grey boxes indicate the inter-quartile range and the
bars indicate the 95% range.
BSIC, blood spot iohexol clearance; GFR, glomerular filtration rate; MDRD, modification of diet and
renal disease formula; Cyc-GFR, GFR estimated from blood cystatin c concentration
Analysis is restricted to individuals who returned 2 analysable blood spot iohexol samples and had
measurements of blood creatinine and cystatin c concentrations (n=106).
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Chapter 4: Glomerular filtration rate and risk factors for
cardiovascular disease
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4.1 Study aims
In the Chronic Renal Failure in Birmingham study, nephrology outpatients with an
elevated serum creatinine (>130 pmol/1) had lower blood HDL-cholesterol
concentrations and higher blood concentrations of triglyceride, homocysteine, fibrinogen
and C reactive protein, compared to healthy controls (5;54). Furthermore, among those
with chronic kidney disease, a graded relationship was observed between lower GFR
(assessed by higher blood concentration of creatinine or cystatin c) and lower blood
concentration ofHDL-cholesterol and higher blood concentration of homocysteine and
fibrinogen (5;54). We aimed to extend these findings by examining the cross sectional
relationships between measures of GFR (including an exogenous tracer based method)
and cardiovascular risk factors in a sample of individuals without chronic kidney disease.
This study aims to;
1. examine the cross-sectional relationships between measures ofGFR and the following
risk factors for cardiovascular disease
(i) blood pressure
(ii) blood concentration of lipids and apolipoproteins,
(iii) blood concentration of fibrinogen, C reactive protein and homocysteine
(iv) markers of body composition
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2. assess how these relationships are affected by the method used to measure GFR
(blood spot iohexol clearance, creatinine-based estimates ofGFR, or GFR
calculated from serum cystatin C concentration).
Methods
This study was conducted among volunteers taking part in the pilot study described in
chapter 3. The recruitment methods, participant characteristics and data collection
techniques are described in section 3.2. Participants were included in this study if they
had no missing values for GFR measured by blood spot iohexol clearance and estimated
from blood concentrations of cystatin c and creatinine (n=106). Thirty six percent of the
participants in this study the were receiving either homocysteine lowering treatment
(folic acid and vitamins B6 and B12) or placebo as part of the double blinded Study of
the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
(SEARCH). Such treatment was recorded as 'possible folic acid'.
4.1.1 Laboratory methods
Details of the blood spot collection and storage methods are given in sections 3.2.3.7
and 3.2.3.9. The methods used to analyse blood iohexol concentration in dried capillary
blood spots, and the calculations used to estimate GFR from 2 spots are outlined in
section 2.2.3.1. Blood samples were collected as outlined in section 3.2.3. Whole blood
was removed from the EDTA sample for analysis of haematocrit and haemoglobin.
After centrifuging, aliquots of plasma were removed from the EDTA sample for analysis
of concentration of creatinine, cystatin c, total cholesterol, High Density Lipoprotein
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(HDL)-cholesterol, Low Density Lipoprotein (LDL)-cholesterol, triglycerides, apo-
lipoproteins A] and b, C-reactive protein and fibrinogen, and an aliquot of plasma
removed from the sodium fluoride EDTA blood sample for analysis of homocysteine.
The remaining EDTA and sodium fluoride EDTA plasma samples were transferred into
cryovials and stored at -80°C for future use. GFR was calculated from blood creatinine
concentration by the abbreviated MDRD formula (Table 1.2) and from blood cystatin c
concentration by the formula by Hoek et al (Table 1.5). Eighty eight percent of samples
were processed on the same day as collection with the remaining samples processed the
following day. Table 4.1 provides details of the laboratory methods used in this study.
4.1.2 Statisticalmethods
Data was analysed using Stata v8.2 (StataCorp, Texas, USA). Continuous variables were
assessed for normality by visual inspection of a normal plot and by a Shapiro-Wilk test.
Variables which were not normally distributed (blood HDL-cholesterol, LDL-
cholesterol, total-cholesterol, apolipoprotein Aj, apolipoprotein b and triglyceride
concentrations, weight, and body mass index) were transformed by taking a logarithm to
the base 10 and the log[variable] then tested for normality. The normal plot was also be
used to visually assess for outliers. The value of any outlier more than 3 standard
deviations away from the mean was double checked against the source data and, if there
was reason to believe that the value was spurious, it was excluded. For the analysis
involving C-reactive protein (CRP), one participant with an outlying value of 47 mg/L
was excluded since this value was likely to reflect an acute rise in CRP. Normally
distributed variables were expressed as mean ± standard deviation. Variables which
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were not normally distributed were expressed as median (interquartile range).
Differences in proportions across tertiles ofGFR were compared by a chi squared test
for trend while differences in mean values across tertiles of GFR were compared using
ANOVA test for trend (using the geometric mean if the variable was not normally
distributed). Pearson correlations and least squares linear regression was used to
examine relationships between continuous variables. No quantitative adjustments for
multiple testing were performed but due allowance for this was made in the




The mean±standard deviation GFR measured using blood spot iohexol clearance (BSIC-
GFR), estimated by the MDRD formula (MDRD-GFR) and estimated from the blood
concentration of cystatin c (cyc-GFR) was 103.1±28.3, 90.5±18.1 and 92.0±19.3
ml/min/1.73m2 respectively and the distributions of these GFR measures are shown in
chapter 3, figure 3.7.
The participant characteristics and cardiovascular risk factors by tertiles of BSIC-GFR
are shown in table 4.2. Those with lower BSIC-GFR were older, more likely to have a
prior history of cardiovascular disease and were more likely to be receiving lipid,
cholesterol or homocysteine lowering medication. All 3 GFR measures correlated
strongly with age (r=-0.31 [p=0.002] for BSIC-GFR, r=-0.40 [pO.OOl] for MDRD-GFR
and r=-0.49 [pO.OOl] for Cyc-GFR).
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4.2.2 Measures ofGFR and 'traditional' cardiovascular risk factors
No correlations could be detected between any of the GFR measures and diastolic blood
pressure, systolic blood pressure, or blood concentration of total-cholesterol, LDL-
cholesterol or apo-lipoprotein b. Summary statistics describing the relationships between
blood concentrations of HDL-Cholesterol, apolipoprotein Ai and triglyceride, and each
of the GFR measures are shown in table 4.3. Scatter plots showing the relationship
between the GFR measures and blood triglyceride concentration are shown in figure 4.1.
4.2.2.1 Blood Spot Iohexol Clearance GFR (BSIC-GFR) and blood lipid
concentrations
The correlations between BSIC-GFR and blood concentration of HDL-cholesterol and
apolipoprotein Ai were not statistically significant (r=0.167 [p=0.087] and r=0.083
[p=0.397] respectively). However, a correlation was observed between blood
triglyceride concentration and BSIC-GFR (r=-0.247 [p=0.011]. After adjustment for age
and sex, a 30 ml/min/1.73m2 lower BSIC-GFR was associated with 4.9% higher blood
triglyceride concentration, although the 95% confidence interval (CI) for this estimate
(1.1% lower to 11.0% higher) crossed zero (Table 4.3).
4.2.2.2 MDRD-eGFR and blood lipid concentrations
Blood concentration ofHDL-cholesterol and apolipoprotein Aj were not significantly
correlated with MDRD eGFR (r=0.136 [p=0.166] and r=0.075 [p=0.113] respectively).
A relationship was observed between MDRD eGFR and blood triglyceride concentration
(r=-0.278 [p=0.004]). After adjustment for age and sex, a 30 ml/min/1,73m lower
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MDRD-eGFR was associated with an 11.5% (95% CI 1.6 to 21.3%) higher blood
triglyceride concentration (Table 4.3).
4.2.2.3 Cystatin C eGFR (cyc-eGFR) and blood lipid concentrations
Cyc-eGFR was correlated with blood concentration ofHDL-cholesterol and
triglycerides (r=0.390 [p<0.001] and r=0.392 [p<0.001] respectively). A similar
correlation was seen between cyc-eGFR and apolipoprotein Ai r=0.283 [p=0.003]. After
adjustment for age and sex, a 30 ml/min/1.73m2 lower cyc-eGFR was associated with a
6.5% (95% CI 2.7-10.3%) lower blood concentration ofHDL cholesterol, a 3.8% (95%
CI 1.5-6.2%) lower blood apolipoprotein A] concentration and a 14% (95% CI 4.2-24%)
increase in blood triglyceride concentration (Table 4.3).
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4.2.3 Measures ofGFR and novel cardiovascular 'biomarkers'
Summary statistics describing the relationships between blood concentrations of
homocysteine, CRP and fibrinogen and the 3 measures GFR are shown in table 4.4.
Scatter plots showing the relationship between the GFR measures and blood
homocysteine concentration are shown in figure 4.2.
4.2.3.1 BSIC-GFR and novel cardiovascular 'biomarkers'
No correlation between BSIC-GFR and the blood concentrations of CRP or fibrinogen
could be detected (r= -0.149 [p=0.128], r=-0.141 [p=0.150] respectively, table 4.4).
However, an inverse correlation between BSIC-GFR and blood homocysteine
concentration was observed (r=-0.415[p<0.001], table 4.4). After adjustment for age and
sex, a 30 mlmin/1.73m2 lower BSIC-GFR was associated with a 5.3% (95% CI 3-7.4%)
higher blood homocysteine concentration (Table 4.4).
4.2.3.2 MDRD-GFR and novel cardiovascular 'biomarkers'
No correlation between MDRD GFR and blood concentration of CRP could be detected
(r=0.140 [p=0.151], table 4.4). However, MDRD-eGFR correlated with blood
concentration of both fibrinogen (r=-0.378 [p<0.001]) and homocysteine (r=-0.414
[p<0.0001]) (Table 4.4). After adjustment for age and sex, a 30 mlmin/1.73m2 lower
MDRD-GFR was associated with a 0.21 g/1 (95% CI 0.02-0.40 g/1) higher blood
fibrinogen concentration and a 9.8% (95% CI 6.4-13.4%) higher blood concentration of
homocysteine (Table 4.4).
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4.2.3.3 Cyc-GFR and novel cardiovascular 'biomarkers'
A correlation was observed between cystatin C eGFR and blood concentrations of CRP
(r=-0.304 [p=0.002]), fibrinogen(r=-0.404 [pO.OOl]) and homocysteine (r=-0.422
[p<0.0001) (Table 4.4). After adjustment for age and sex, a 30 ml/min/1.73m2 higher
cyc-eGFR was associated with a 19.6% (95% CI 5-34.3%) increase in blood
concentration ofCRP, a 10.0% (95% CI 6.3-13.6%) increase in blood homocysteine
concentration and a 0.28 g/1 (95% CI 0.09-0.47 g/1) higher blood fibrinogen
concentration.
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4.2.4 Measures ofGFR and markers ofbody composition
Summary statistics describing the relationship between the 3 GFR methods and body
mass index (BMI), waist circumference and percentage body fat measured by
bioimpedence are shown in table 4.5. Scatter plots showing the relationship between
measures ofGFR and waist circumference are shown in figure 4.3.
No correlation could be detected between BSIC-GFR and BMI, waist circumference or
percentage body fat (Table 4.5). Similarly, no correlation could be detected between
MDRD-GFR and either BMI or waist circumference. MDRD-GFR was negatively
correlated with percentage body fat (r=-0.307 [p=0.002]) but after adjustment for age
and sex, lower MDRD-GFR was not associated with greater body fat (P coefficient
0.043 per mFmin/1.73m2 lower MDRD-GFR [p=0.284], table 4.5).
Cyc-GFR, however, was negatively correlated with BMI (r=0.330 [p=0.001 ]), waist
circumference(r= -0.507 [p<0.001 ]) and percentage body fat (r=-0.242 [p=0.014]). After
adjustment for age and sex, a 30 ml/min/1.73m2 lower cyc-eGFR was associated with a
2.7% (95% CI 0.1-5.3%) higher BMI, a 6.1cm (95% CI 2.4-9.9 cm) larger waist and
3.5% (95% CI 1.2-5.8%) greater body fat (Table 4.5).
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4.3 Discussion
This study demonstrates that, in a small group of 24 to 77 year olds, measures ofGFR
were positively correlated with blood HDL-cholesterol and apoliprotein Ai
concentrations, and were inversely correlated with blood concentrations of triglyceride,
CRP, fibrinogen, and homocysteine.
4.3.1 Potential clinical relevance ofthese associations
After adjustment for age and sex, a 30 ml/min/1,73m lower GFR was associated with a
0-7% lower blood HDL-cholesterol concentration, a 5-14% higher blood triglyceride
concentration, a 0-20% higher blood concentration ofCRP, a 5-10% higher blood
homocysteine concentration and a 0-0.28 g/1 higher blood fibrinogen concentration,
depending on the GFR measure examined (Tables 4.3 and 4.4). While modest, some of
these changes in cardiovascular risk factors could be associated with clinically relevant
increases in cardiovascular risk.
In observational studies a 0.1 mmol/1 decrease in HDL cholesterol (approximately equal
to a 7% decrease in this study) was associated with a 20% increased risk of coronary
heart disease (48). For triglycerides, a 1 mmol higher blood concentration is associated
with a 14% and 37% increased risk of cardiovascular disease in men and women
respectively in observational studies (50). Therefore, a 14% increase in blood
triglyceride concentration in this study (approximately equal to 0.15 mmol/1 higher
blood concentration) might be associated with a 1.02-1.06 fold increase risk of
cardiovascular disease. In observational studies an increase in CRP of around 1.4 mmol/1
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is associated with a 1.9 fold increase in risk of coronary artery disease (51). Therefore a
20% higher CRP concentration in this study (approximately equal to only a 0.16 mg/1)
might be associated with roughly a 1.1 fold increase in risk of coronary artery disease.
In observational studies, a 25% higher blood homocysteine concentration is associated
with a 1.11 fold higher risk of ischaemic heart disease (69), while a lg/1 higher blood
fibrinogen concentration is associated with a 1.8 fold increase risk of coronary disease
(55). Therefore, a 10% higher blood homocysteine concentration and 0.28 g/1 higher
blood fibrinogen concentration a might be associated with a 1.04 fold and 1.22 fold
increase in ischaemic heart disease risk respectively. If these risks were additive one
might expect the change in risk factors accompanying a 30 ml/min/1.73m2 lower GFR to
be associated with a small, but potentially clinically relevant, increase in the risk of
cardiovascular disease.
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4.3.2 Possible pathophysiological basis for these associations
This study demonstrates a relationship between measures of lower GFR and higher
blood concentrations of triglycerides, CRP, fibrinogen, and homocysteine, and lower
blood concentrations ofHDL-cholesterol and apoliprotein A], In this cross-sectional
study, it is not possible to explore whether these adverse cardiovascular risk factors
might be a cause or a consequence of lower GFR. However, a number of lines of
evidence suggest that substantial loss ofGFR in chronic kidney disease (CKD) may
result in dyslipidaemia, a pro-inflammatory state and increased blood homocysteine
concentrations.
ESKD is associated with impaired clearance of triglyceride rich apolipoprotein B
containing very low density lipoprotein (VLDL) and intermediate density lipoprotein
(IDL) particles (32;43) (Figure 4.4). These abnormalities are probably the result of
decreased activity of the key enzymes which regulate the metabolism of blood
triglycerides, lipoprotein lipase (LP) and hepatic lipase (HL) (Figure 4.4) (32;46;49). In
addition, changes in the composition ofVLDL particles, particularly increased surface
apolipoprotein Cm, in ESKD (47) may further impair their clearance (46). The
dyslipidaemia of ESKD is also characterised by impaired maturation ofHDL particles
(32;46) resulting in low blood concentration of the mature HDL2 particles (49) (Figure
4.4). Reduced activity of the enzyme lethicin cholesterol acetyltransferase(LCAT) in
ESKD is likely to be at least partly responsible for this abnormal reverse cholesterol
transport (25;32). Evidence from experimental models ofCKD in animals suggests a
causal relationship between loss of GFR and these lipid abnormalities (32).
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Experimental CKD is associated with reduced activity and tissue gene expression of LP
(229;230), HP (231) and LCAT (232;233) and decreased hepatic production of
apolipoprotein Ai (32) (Figure 4.5). Evidence suggests that these abnormalities in lipid
metabolism occur early in the natural history ofCKD. In the Chronic Renal Failure in
Birmingham (CRIB) study, blood HDL cholesterol was 13% lower and blood
triglyceride concentration 58% higher among those with CKD (defined as nephrology
clinic outpatients with a creatinine >130 pmol/1) compared to age and sex matched
healthy controls (5). In a cross sectional analysis from the Cardiovascular Health Study,
a population based cohort of individuals aged >65 years in the United States, individuals
with CKD (defined as a serum creatinine concentration >133 pmol/1 in men or >115
pmol/1 in women) had higher blood HDL-cholesterol and lower blood triglyceride
concentrations than those without CKD (59).
Compared to healthy controls, individuals with ESKD have substantially higher blood
concentrations of CRP (53) and fibrinogen (56). In the CRIB study, blood
concentrations of fibrinogen and CRP were 0.8g/L and 1.5mg/L higher respectively
among those with CKD than age and sex matched controls (54), and, in the
Cardiovascular Health Study, CKD was associated with higher blood concentrations of
inflammatory markers (CRP, fibrinogen and interleukin-6) after adjustment for age, sex
and other cardiovascular risk factors (59). Potential reasons for these findings include
reduced clearance (234) or increased production as a result of systemic inflammation
(235;236). It is increasingly recognised that CKD is associated with a state of
generalised systemic inflammation (235;236). Postulated reasons for this include an
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effect of renal disease itself, the result of other associated conditions (such as diabetes or
cardiovascular disease), or, among those with ESKD, pro-inflammatory effects of the
dialysis treatments per se (52;235). A number of mechanisms by which renal disease
might cause increased inflammation have been postulated, including the reduced
clearance of pro-inflammatory cytokines (235) and the accumulation of advanced
glycosylation end-products (AGE) (237-239).
Blood homocysteine concentration is markedly elevated among individuals with CKD
(27). In one study, blood homocysteine concentration was 22.7 pmol/1 among 25
individuals receiving haemodialysis therapy, compared to 9.5 pmol/1 among 25 age and
sex matched controls drawn from the Framingham study (240). In the CRIB study
plasma homocysteine concentration was 20.6 pmol/1 among 369 individuals with CKD,
compared to 10.0 pmol/1 among 103 age and sex matched controls (5). Among those
with CKD, plasma homocysteine concentration was strongly correlated with blood
creatinine concentration (5). Among 109 individuals attending a nephrology clinic with
a serum creatinine concentration <130 pmol/1 and GFR 18-205 ml/min/1.73m2 measured
by 51Cr-EDTA clearance, blood homocysteine concentration showed a strong inverse
correlation with GFR independent of age, blood concentration of folate, vitamin B12
and vitamin B6, and proteinuria (partial r = -0.408) (70). A similar strong and graded
relationship between blood homocysteine concentration and GFR has been demonstrated
among the elderly (27), patients with coronary artery disease (241) and individuals with
diabetes mellitus (242). The mechanism by which homocysteine accumulates in CKD
remains unclear (243). Clearance of homocysteine from the plasma is markedly reduced
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in CKD (244) and, in dialysis patients, plasma homocysteine concentration fall rapidly
following renal transplantation (245). However, reduced excretion of homocysteine in
the urine is unlikely to be responsible. Excretion of homocysteine in the urine in health
is minimal (246;247) and, although studies in rats have suggested that homocysteine
may be metabolised by renal tubular cells (248), human studies have failed to support
this hypothesis (249). Extra-renal effects of uraemic toxins on homocysteine metabolism
have been postulated, this may not explain the strong relationship seen between plasma
homocysteine concentration and GFR among individuals with a relatively preserved
renal function (243).
4.3.3 Impact ofchoice ofGFR measure
Since a large number of statistical comparisons were made in this exploratory study,
small differences in the (3 regression coefficient or the correlation coefficient should not
be over interpreted. However, two key points should be noted.
First, the relationships between BS1C-GFR and blood HDL-cholesterol apolipoprotein
Ai, triglyceride, CRP, fibrinogen and homocysteine concentrations were not materially
stronger than the relationships between the MDRD-GFR and these risk factors. Since
GFR estimated from the MDRD formula is only weakly related to true GFR among
individuals without CKD (20; 174), one would expect GFR measured using an
exogenous tracer based method to be more closely related to cardiovascular risk factors.
One could speculate that, since the distribution of BSIC-GFR was wider than that of
MDRD-GFR (Figure 3.7), the difference in cardiovascular risk factors associated per 1
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ml/min/ 1.73m2 might not be comparable. However, expressing the |3 coefficients of
regression analysis per standard deviation increase in GFR measure did not materially
alter the results. Blood spot iohexol clearance accurately reflects traditional iohexol
clearance measured using timed venous blood samples when samples are collected by
trained personnel (Section 2.3.2). However, in this study BSIC-GFR was measured
using dried capillary blood spots collected by participants themselves at home as part of
a pilot study assessing the feasibility of the technique. Twenty two percent of
participants returned 'poor quality' spots and there was evidence that, not only was the
sampling time recorded inaccurately in a proportion of individuals, but that large
discrepancies between the actual and recorded sampling time may have occured
(Section 3.4.2). Therefore, it is likely that error in the BSIC-GFR method resulted in a
weaker relationship between BSIC-GFR and cardiovascular risk factors than would be
observed if true GFR was measured.
Second, the relationships between Cyc-GFR and BMI, waist circumference and
percentage body fat measured by bioimpedance, were substantially stronger than that
seen with either BSIC-GFR or MDRD-GFR after adjustment for age and sex. The
relationship between increased body fat and GFR is complex. In cross-sectional studies,
higher BMI is associated with a normal or increased GFR but increased renal plasma
flow to GFR ratio indicating hyper-filtration (250;251). Individuals with higher BMI,
particularly those with central obesity, are also more like to have microalbuminuria
(252). Histological examination of renal tissue from obese kidney donors and animals
fed a high fat diet show structural glomerular changes, particularly glomerular expansion,
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compared to non-obese controls (253;254). These early changes associated with obesity
may lead on to glomerulosclerosis and progressive renal damage and in prospective
studies, higher BMI is associated with an increased risk of developing chronic kidney
disease (255;256) and end stage renal failure (257) decades later. However, some studies
have suggested that blood cystatin c concentration might be related to body composition
independent of GFR. In a large community sample, weight was related to blood cystatin
c concentration after adjustment for measured creatinine clearance (141). In addition,
among individuals with CKD, lean body mass was related to blood cystatin c
concentration independent of inulin clearance (258). One explanation of these, and our
findings, could be increased cystatin c production among those with greater body fat. In
addition, in this study, cyc-GFR tended to be more strongly associated with blood lipids
and inflammatory markers, particularly blood HDL-cholesterol and CRP concentrations,
than BSIC-GFR or MDRD-GFR (Tables 4.3 and 4.4). Cystatin c is increasingly
employed to assess GFR in large scale epidemiological studies. Larger samples which
assess a reference GFR, blood cystatin c concentration and cardiovascular risk factors,
including assessment of body composition, are needed to properly determine the non-
GFR determinants of blood cystatin c concentration.
4.3.4 Weaknesses ofthe study
Three main weaknesses of this study should be considered. First, the study included only
106 individuals. The failure to detect relationships, for example, between markers of
GFR and blood pressure, could result from a lack of statistical power.
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Second, this study may underestimate the strength of the relationships between measures
of GFR and blood concentrations of lipids and homocysteine since those with lower
GFR were more likely to be taking lipid lowering medication or folic acid (Table 4.2).
Similarly, the failure to detect a relationship between measures ofGFR and blood
pressure probably results from the greater antihypertensive use among those with lower
GFR (Table 4.2).
Third, since the data was collected as part of a pilot study to assess the feasibility of
using the blood spot iohexol clearance technique in which participants collect the finger-
prick capillary blood samples themselves at home, no 'gold-standard' GFR was
measured. The aim of this pilot study was to explore the relationships between the
difference measures ofGFR and cardiovascular risk factors while assessing the
feasibility of the BSIC method. Larger scale studies in which a fully validated GFR
method is measured would enable further assessment of the relationship between GFR
and cardiovascular risk factors and also, with long term follow-up, determine the true
impact of GFR on the cardiovascular outcomes and death.
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4.4 Summary of key findings
■ In this sample, measures of GFR were positively correlated with blood HDL-
cholesterol and apoliprotein Aj concentrations, and were inversely correlated with
blood concentrations of triglyceride, CRP, fibrinogen, and homocysteine.
■ The magnitude of the change in these cardiovascular risk factors accompanying a
30ml/minl.73m lower GFR could be associated with a small, but potentially
clinically relevant, increase in risk of cardiovascular disease.
■ GFR measured by blood spot iohexol clearance was not more strongly related to
cardiovascular risk factors than that estimated from the MDRD formula, probably as
a result of error in the BSIC-GFR method used in this study.
■ GFR estimated from blood cystatin c concentration tended to be more strongly
correlated with blood lipids and inflammatory markers than GFR measured by the
other two methods.
■ Measures of body fat are strongly correlated with GFR estimated from cystatin c
concentration, but not with either GFR estimated from the MDRD equation or
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Table 4.2: Cardiovascular risk factors by tertiles of glomerular filtration rate measured








n 106 35 35 36
GFR (ml/min/1.73m2) 103.1±28.3 74.3±14.8 101.1±5.8 134.1±18.2
Age (years) 54.3±14.4 59.9±14.3 53.2±13.1 49.7±14.1 0.003 f
Female 47% 41% 49% 50% 0.552*
Prior CVD 36% 56% 29% 25% 0.01*
Lipid lowering treatment 43% 64% 34% 31% 0.006*
BP lowering treatment 45% 63% 37% 25% 0.001*
Possible folic acid 35% 53% 26% 25% 0.019*
Current smoker 7% 6% 6% 8% 0.659*
Ex-smoker 42% 50% 34% 40% 0.471*
Systolic BP (mmHg) 129.9±18.6 129.1±17.2 129.8±20.2 130.8±18.7 0.668f
Diastolic BP (mmHg) 78.7±10.4 77.4±10.0 78.2±10.8 80.4±10.4 0.236f
BMI (kg/m2) 26.2(23.5-29.0) 26.4 (23.0-28.9) 25.8 (23.6-28.9) 26.4 (24.0-29.0) 0.85If
Waist (cm) 91.2±13.0 93.4±13.9 90.8±11.5 89.4±13.6 0.192f
Percentage body fat 29.6±8.6 30.8±9.8 28.3±8.9 29.4±6.8 0.439f
Total-C (mmol/l) 4.4 (3.6-5.1) 4.6(3.6-5.1) 4.4 (3.6-5.0) 4.3 (3.8-5.1) 0.911f
LDL-C (mmol/l) 2.3 (2.0-3.1) 2.4(1.7-3.0) 2.5 (2.1-3.2) 2.3 (2.0-3.2) 0.5821
F1DL-C (mmol/l) 1.3 (1.0-1.6) 1.3 (1.0-1.6) 1.2 (1.1-1.7) 1.4(1.0-1.6) 0.9131
Apo b/apo a! ratio 0.59 (0.47-0.73) 0.53 (0.44-0.74) 0.60 (0.53-0.70) 0.57 (0.47-0.73) 0.7831
Triglyceride (mmol/l) 1.12(0.68-1.91) 1.28 (0.75-2.35) 1.13 (0.88-1.84) 0.97 (0.49-1.56) 0.011
Fibrinogen (g/l) 3.2±0.6 3.4±0.7 3.1±0.5 3.1±0.6 0.0461
CRP (mg/l) 0.8 (0.7-1.0) 1.0 (0.8-1.2) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.497f
Homocysteine (/xmol/l) 9.6(8.3-11.2) 10.6(8.4-14.3) 9.8(8.8-11.7) 8.9 (7.9-10.1) 0.001
Data are expressed as mean ± standard deviation, median (range) or percentage
*
p value for Chi squared test for linear trend
t p value for ANOVA test for linear trend (based on geometric mean if variable not normally distributed)
CVD, cardiovascular disease; BP, blood pressure; mmHg, millimeters ofmercury; BMI, body mass index;;
kg, kilograms; m, meters; cm, centimeters; Total-C, total cholesterol, LDL-C, low density lipoprotein
cholesterol; HDL-C, high density lipoprotein cholesterol; Apo, apolipoprotein; CRP, C-reactive protein.
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0.167(p=0.087) 0.136(p-0.1 5) 0.390(p<0.0 1)
0.00040± . 041(p= .327) 0.00130± . 0066(p= . 53) 0.00217± . 0065(p= . 01)
Log[triglyceride(mmol/l)] Log[triglyceride(mmol/l)] Logftriglyceride(mmol/l)]
BSIC-GFR MDRD-eGFR Cyc-eGFR
-0.247(p=0. 11) -0.278(p=0. 04) -0.392(p<0. 01)




0.00018± . 025(p= .4 7) 0.00093± . 041(p= . 24) 0.00128± . 0040(p= . 02)
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Figure 4.1: Scatter plots showing the relationship between measures of glomerular
filtration rate and Log [blood triglyceride concentration]
a. Blood Spot Iohexol Clearance GFR (BSIC-GFR)
40 60 80 100 120 140 16
BSIC-GFR (ml/min/1.73m2)
b. GFR estimated from the Modification of Diet in Renal Disease formula (MDRD-
eGFR)
80 100 120 140 160 180 200
Cyc-eGFR (ml/min/1.73m2)
c. GFR estimated from blood cystatin c concentration (cyc-eGFR)
100 120 140 160 180 200
Cyc-eGFR (ml/min/1.73m2)
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Figure 4.2: Scatter plots showing the relationship between measures of glomerular
filtration rate and Log [homocysteine concentration]













♦ ♦♦ j« ♦
► ♦ ♦ ♦ *
40 60 80 100 120 140 160
BSIC-GFR (ml/min/1.73m2)
180





















40 80 100 120 140 160
MDRD-eGFR (ml/min/1.73m2)







♦ # ^ '
'♦V









Figure 4.3: Scatter plots showing the relationship between measures of glomerular
filtration rate and waist circumference
a. Blood Spot Iohexol Clearance GFR (BSIC-GFR)
80 100 120 140 160
BSIC-GFR (ml/min/1.73m2)
b. GFR estimated from the Modification of Diet in Renal Disease formula (MDRD-
eGFR)
80 100 120 140 160
MDRD-eGFR (ml/min/1.73m2)
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Chapter 5: Estimated glomerular filtration rate and the risk of
major vascular events and all-cause mortality
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5.1 Aims of the study
Several prospective cohort studies have suggested that mild-to-moderate reductions in
GFR may be associated with a modest, but clinically important, increase in the risk of
major vascular events (17; 18;261 ;262) and all-cause mortality (263) but previous meta¬
analyses of such studies (264;265) have been limited by a number of methodological
problems.
First, different studies have tended to use different cut points for defining categories of
renal function (which make direct between-study comparisons unreliable). Furthermore,
estimated GFR is heavily dependent on the laboratory calibration of the creatinine assay
(167), and, to a lesser extent, the estimation method used (266), further increasing the
likelihood of misclassification between renal function categories when comparing
different studies. In addition, studies considering more than two renal function groups
typically report relative risks compared with a single reference group assigned the
relative risk of 1 with no associated error. While standard practice, this makes it
difficult to assess the true nature of dose-response risk relationships.
This quantitative meta-analysis aims to overcome these problems through consideration,
not of absolute eGFR levels, but of within-study proportional differences in eGFR,
which are less susceptible to biases introduced by laboratory creatinine calibration
differences between studies, and by differences in the cut-points used to define renal
function groups. Furthermore, by consideration of the number of people and number of
events in each group, dose-response risk relationships are constructed that take account
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of the information in all risk groups, including the reference groups. Using these
methods, this study aims to summarise the risk of death and major vascular events
associated with lower eGFR across the published studies, and compare these risks
between different types of study.
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5.2 Methods
5.2.1 Search strategy and inclusion criteria
Studies assessing the relationship between eGFR (estimated using either the MDRD
formula (114; 116) or the Cockcroft-Gault formula (115)) and major cardiovascular
events (MVE; see below) or all cause mortality were identified from MEDLINE by
searching PubMed (1966 to 1st August 2006), using a combination of terms relating to
cardiovascular disease or death, creatinine or eGFR, and cohort studies (Table 5.1). The
MEDLINE search was complemented by reviewing the reference lists of subsequently
retrieved papers, and, where necessary, through contact with study authors. The pre-
specified criteria for inclusion into the meta-analysis were studies;
■ assessing all-cause mortality or major vascular events (defined as myocardial
infarction; unstable angina; stroke; transient ischaemic attack; coronary or non
coronary revascularisation; or cardiovascular, cardiac or coronary death),
■ of at least 500 individuals,
■ involving at least 1 year planned follow-up, and
■ which reported risk associations that were adjusted for at least age and sex.
Studies were excluded if they only analyzed eGFR as a continuous variable or if the
study was conducted solely among individuals with existing chronic kidney disease or
other serious non-cardiovascular disease likely to be related to kidney dysfunction (e.g.
chronic liver disease).
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5.2.2 Data extraction and definition of terms
The following data were extracted from each study;
■ details of the study population,
■ mean follow-up,
■ the type and total number of outcomes,
■ details of each category of eGFR (the cut points used, the mean eGFR for the group
and the number of individuals and outcomes in the group),
■ the most fully adjusted relative risk estimates and confidence intervals associated
with each comparison group, and
■ the confounders adjusted for in the analysis.
If a study reported results for both Cockroft Gault and MDRD eGFR, the results using
the MDRD formula were extracted. Studies were considered to be a 'prospective cohort
study' if the baseline data were prospectively collected by study personnel but not as
part of a randomized controlled trial. Studies which analysed registry data or
retrospectively extracted data from hospital medical records were considered 'routine
data' sources. In the case of duplicate reports from the same study population, the first
published paper was used unless the later report contained additional events.
5.2.3 Statistical methods
The primary analyses involved estimating the relative risk ofMVE and all-cause
mortality associated with a 30% lower eGFR. First, the proportional difference in eGFR
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for each comparison group compared to the reference group was identified and then, for
each study, the risk associated with a 30% lower eGFR was calculated.
5.2.3.1 Calculating the proportional difference in GFR for each comparison group
Where the mean eGFR in each group was not provided, it was estimated either through
knowledge of the mean and standard deviation of the overall distribution, or else through
the proportions of the population falling within each group (see section 5.2.3.2 below)
assuming, unless stated otherwise in the publication, that eGFR followed a normal
distribution since this was the distribution observed in 20536 people at high-risk of
vascular disease who were enrolled into the Heart Protection Study (Figure 5.1). In one
study, a log-normal distribution was assumed rather than a normal distribution because
the authors explicitly stated that the distribution was positively skewed (the mean values
in this study therefore represent geometric means). This approach was validated using
data from the studies that did report mean eGFR in each group (Figure 5.2).
5.2.3.2 Estimating the mean eGFR level in groups defined by 'cutoff values
IfX has a normal distribution with mean fJ and standard deviation (7, then it follows that
Z -{X - fj)l a |ias a normai distribution with mean 0 and standard deviation 1. Now
let X' be the same as X but constrained to lie between two cutoff values a and b. The
expected value ofX' is equal to E(^X\a<x <b) = M + aE(Z \ < Z < b-f) Thg
a-fj b-/j
probability density function of Z conditional on Z taking a value between and CT is:
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where <j) is the standard normal density function and ® is the standard normal cumulative
distribution function. Therefore, the expected value ofX' is equal to:
u + 7 — \wd)wdw
-„ + Xe-Y&1 _.e-&£
<i)
However, in studies in which the overall mean and standard deviation were not stated,
these were first estimated from the known proportions of the population falling within
each exposure group. For instance, if a study ofN participants reported three exposure
groups: eGFR < a; ~ a,< ^ and - b ml/min/1.73m2; with rij, ri2 andns participants










M = a-&.Q-i(pl) (3)
For studies in which more than 3 exposure groups were used however (and hence any
two cutoff values could potentially be used to calculate the mean and standard deviation
of the overall distribution), the mean eGFR in each exposure group was calculated from
estimates of fj and a derived from the nearest two cutoff levels (i.e. either the cutoff
levels actually defining the group or, if the group is one of the tails of the distribution,
from the two nearest cutoff levels).
5.2.3.3 Calculating summary risk estimates for each study
For studies in which participants were separated into one of only two groups, the
reported relative risk (and its 95% confidence interval) was simply rescaled by assuming
a log-linear relationship between log eGFR and risk. For example, if a study reported a
relative risk of 1.5 when comparing individuals with mean eGFR 46 ml/min/1.73m with
individuals with mean eGFR 85 ml/min/1.73m (i.e. a relative difference in mean eGFR
of 46/85 = 0.54), the rescaled relative risk for a 30% lower eGFR would be 1.5 x 0.806 =
1.21 (since 0.54 / 0.67 = 0.806). [Formally, the rescaled relative risk is obtained from the
published relative risk (RR) through the equation exp(ln(0.67) x ln(RR) / ln(a/b)), where
b is the mean exposure level in the reference group and a is the mean exposure level in
the single comparison group].
For studies in which more than two groups were considered, the relative risk was
derived from the slope of a weighted linear regression through the reported (log) relative
risk estimates (including through the relative risk of 1 corresponding to the reference
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group) against log eGFR. Weights for the groups (including for the reference group)
were obtained by reconstructing the approximate (uncorrelated) standard errors of the
crude 'floating absolute risks' (267). Unfortunately, in all of the studies, relative risks
were reported relative to a single reference group (assigned the relative risk of 1) with no
associated error. Not only does this make the confidence intervals around the relative
risk estimates correlated, but, more importantly, it also makes it impossible to determine
the amount of'statistical information' in the reference group (and hence impossible to
determine the appropriate weighting for the reference group). Logistic regression was
therefore used to 're-analyze' each study, relating the exposure group to the number of
subjects and events observed in each group. This provided a variance-covariance matrix
of the estimated (crude) log odds ratios which was used to calculate approximate
'floated' standard errors for the log odds ratio in each group (including the reference
group) (267). While the odds ratios obtained from these analyses would be expected to
differ from the adjusted relative risks actually published, their floated standard errors
should be close to the true floated standard errors because they are chiefly determined by
the number of subjects and events in each group, and should therefore be relatively
unaffected by adjustment for confounders. The risk ofMVE or all-cause mortality
associated with a 30% lower eGFR was then estimated from the slope provided by the
weighted linear regression of the published log relative risks on the (log) mean exposure
levels (with weights equal to the reciprocal of the square of the floated standard errors,
i.e. inverse variance weighted). However, since these weights were known exactly (and
not just relatively), the standard error of the slope needed to be corrected by dividing it
by the square root of the mean squared error (268).
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5.2.3.4 Assessing heterogeneity between studies
Given the summary log relative risk bt (and its variance v,-) for each study (see above),
heterogeneity between the different studies was assessed by calculating X = Z(w,bf) -
Z(Wibi)2 / ZWj (where W, = 1/vi), and testing this against a chi-squared distribution with k-
1 degrees of freedom (where k is the number of studies). This was done separately
within particular types of study (e.g. prospective cohort studies, randomised controlled
trials), and also separately in populations with and without prior vascular disease. The
'pooled' log relative risk across different studies was calculated by 2W,b,/2W, (with
variance equal to 1 / 2W,).
5.2.3.5 Regression dilution bias
With the exception of one study (261), in which analyses were performed using time-
dependent covariate techniques, all results presented in this paper are derived purely
from analyses of baseline eGFR measures. The potential effects of regression dilution
bias (i.e., the tendency for baseline measures to result in underestimation of associations
with long-term 'usual values' (269)) on the findings of the meta-analysis were
considered through examination of repeated eGFR measurements taken an average of





Figure 5.3 summarizes the search retrieval process. Out of 9583 abstracts reviewed, 124
papers were retrieved for further examination, ofwhich 43 met the inclusion criteria,
with 5 more being identified from the reference lists. Contained within these 48
manuscripts was information relating to 53 different studies. Mean eGFR in the
different risk groups was presented (or else sufficient information was provided to allow
its estimation) for 48 of these studies, including 12 prospective cohort studies, 19
randomised controlled trials and 17 studies from 'routine' sources (Table 5.2). In
studies where 'pooled' analyses had been performed in the original papers (18;271 ;272),
authors were contacted to provide study-specific results, while in the largest study (263),
where age specific analyses had been performed, the authors were contacted to provide
results separately for people with and without prior vascular disease, both age-
specifically, and overall for all ages.
5.3.2 eGFR and the risk ofmajor vascular events
Twenty six studies (12 cohort studies, 11 trials and 3 routine data sources) comprising a
total of 1 372 820 individuals assessed the relationship between eGFR and major
vascular events. Among these studies, 842 762 individuals (61% of all participants)
were included in the reference groups, in which the weighted mean (SD) eGFR across
9 9
the studies was 83 ml/min/1.73m (12.8 ml/min/1.73m ). Figure 5.4a shows the overall
dose-response relationship between MVE risk and proportional differences in eGFR
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from this reference level; Figure 5.5 shows study-specific estimates of the relative risk
associated with a 30% lower eGFR, grouped by study design and by history of prior
vascular disease. A strong, graded, approximately log-linear relationship was observed
across the different studies, with lower eGFR levels consistently related to higher MVE
risk, at least down to eGFR levels of about 25-30 ml/min/1,73m2 (i.e., about 60-70%
lower than average reference levels) (Figure 5.4a). A 30% lower eGFR level (e.g., from
~80 to 55 ml/min/1.73m2) was associated with a 20-30% increased risk ofMVE,
irrespective of study design, or of history of prior vascular disease (Figure 5.5).
However, substantial heterogeneity was observed within the prospective cohort studies
that could not be accounted for by separation according to prior disease. The two
studies from routine data sources in people with prior vascular disease also gave
apparently discordant results. There was no significant heterogeneity between the
findings of the randomised controlled trials however (combined relative risk among
studies of patients with prior disease: 1.19 [95% CI 1.16 to 1.21] for a 30% lower eGFR).
5.3.3 eGFR and risk ofall-cause mortality
Forty one studies (9 cohort studies, 15 trials and 17 routine data sources) comprising a
total of 4 061 003 individuals assessed the relationship between eGFR and all-cause
mortality. Among these studies, 2 888 629 individuals (71% of all participants) were
included in the reference groups, in which the weighted mean (SD) eGFR across the
2 2studies was 84 ml/min/1.73 (11.2 ml/min/1.73m ). Figure 5.4b shows the overall dose-
response risk relationship with proportional differences in eGFR and Figure 5.6 shows
the study-specific relative risks associated with a 30% lower eGFR, by study design and
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by history of prior vascular disease. As for MVE, a strong, graded relationship was
observed between lower eGFR levels and progressively higher all-cause mortality risks
(Figure 5.4b), with each 30% lower eGFR level being associated with, on average, about
a 20-30% increase in all-cause mortality (Figure 5.6). Within both the prospective
cohort studies and the routine data sources, there was substantial heterogeneity between
the findings of the individual studies, which could not be accounted for by prior vascular
disease. However, there was again no significant heterogeneity between the findings of
the randomised controlled trials (combined relative risk among studies of patients with
prior disease: 1.23 [95% CI 1.20 to 1.26] for a 30% lower eGFR). The absolute
relevance of reductions in eGFR to all-cause mortality risk was some 3-4 times greater
among populations with prior CVD or other 'high-risk' populations than among
populations without prior CVD (Figure 5.7).
5.3.4 eGFR and all-cause mortality risk by age
In one very large study of eGFR and all-cause mortality (the Veterans Affairs Study
(263); comprising 2.6 million participants [64% of all the individuals followed for all-
cause mortality] and 218 000 deaths [69% of all the deaths]), age-specific results were
made available by the authors. The relative risk of all-cause mortality at different eGFR
levels, among people with and without a history of prior vascular disease, and separately
by age group is shown in figures 5.8 and 5.9: The relative importance of eGFR levels to
all-cause mortality risk decreased as age increased (Figure 5.8). However, since older
people and people with prior vascular disease were at substantially higher absolute all-
cause mortality risk, the absolute relevance of eGFR levels to risk increased markedly
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with age and with prior vascular disease (Figure 5.9). In most people (certainly those
aged >55 years), differences in eGFR levels between about 60 and 90 ml/min/ 1.73m
corresponded to no material increase in all-cause mortality risk. Therefore the
'summary' relative risks shown in figure 5.6 across the entire range of eGFR levels may
overestimate the true relative risks observed at higher eGFR levels and underestimate
the true relative risks at lower levels.
5.3.5 Assessment ofthe potential effects ofregression dilution bias
To investigate the extent that the present use of baseline measurements of eGFR might
result in regression dilution bias, i.e., underestimation of the relation between long-term
'usual' eGFR levels and risk, repeated eGFR measurements taken an average of 4.5
years apart in 7697 patients allocated placebo in the MRC/BHF Heart Protection Study
(270) were examined (Figure 5.10). Mean eGFR (estimated using the MDRD equation
2 2
(114)) was 74 ml/min/1.73m~ at baseline and 67 ml/min/1.73m upon re-measurement.
As expected, patients with initial eGFR levels above the mean had follow-up levels
somewhat nearer to the mean, on average. However, patients with baseline eGFR levels
substantially below the mean had similar (slightly lower) levels upon re-measurement
indicating that their eGFR levels decreased, on average, at a faster rate than that
observed in the population as a whole. The correlation between eGFR levels at baseline
and follow-up was 0.68.
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5.4 Discussion
5.4.1 Overall findings andpotential sources ofbias
This quantitative meta-analysis of cohort studies demonstrates an independent, graded
inverse relationship between proportional differences in baseline eGFR and risk of both
all cause mortality and major vascular events. A 30% lower eGFR was associated with
approximately a 20-30% increase in the risk of both outcomes (Figures 5.5 and 5.6).
However, this may represent a distortion of the true strength of the relationship between
GFR and these outcomes for several reasons.
First, in order to summarise the increase in risk of death and cardiovascular disease
associated with lower eGFR levels between the studies, it was necessary to 'scale' the
reported risk estimates to a standard proportional difference in GFR assuming a log-
linear relationship. Examination of the individual dose response relationships in figure
5.4 suggested that, across most of the range of GFR differences, this was a reasonable
assumption. However, for all cause mortality, small reductions in eGFR, of around 20%
or less (e.g., from -85 ml/min to -70 ml/min), were not associated with any increase in
risk of death. This observation was largely attributable to 2 large 'routine data' sources
(261 ;263), which together contributed 85% of the deaths, in which lower eGFR was not
associated with increased risk of death until eGFR was below 60 ml/min/1.73m .
Therefore, the summary estimates shown in figure 5.6 may well underestimate the
strength of the true relationship between lower GFR and death among those with eGFR
<60 ml/min/1.73m2.
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Second, because most of the studies (all but one) used baseline eGFR in analyses, true
dose-response risk-relationships may have been distorted because of regression dilution
bias (269). To investigate this potential source of bias, GFR estimates over a 4-5 year
period were examined among 7697 individuals allocated placebo in the MRC/BHF
Fleart Protection Study (270). Among those with an eGFR below the population mean
(representative of most of the comparison groups in this meta-analysis), the repeat
measurements were lower than those taken at baseline (Figure 5.10). This difference in
eGFR between baseline and follow up is likely to represent a combination of progression
of renal disease (resulting in the lower eGFR at follow-up) and regression to the mean
(resulting in a higher eGFR at follow-up). The individual contribution of these two
factors, however, is uncertain, and therefore it is difficult to quantitatively assess the
effect that regression dilution bias may have had in the current context, although these
results might underestimate the true strength of the relationship between usual eGFR and
the risk of these outcomes.
Third, since factors other than GFR affect plasma creatinine concentration (diet, muscle
mass and tubular creatinine secretion), for an individual the GFR estimated from serum
creatinine concentration can be widely discrepant from directly measured GFR,
especially among individuals with preserved GFR (>60 ml/min/l,73m2) (20;21), leading
to misclassification of individuals between the groups. In a group of 2095 adults referred
for assessment of GFR by clearance chromium-51 ethylene diamine tetra-acetate (51-Cr-
EDTA) (21), only 71% were correctly classified into K / DOQI CKD stage (>90, 60-89,
30-59, 15-29, <15 ml/min/1.73m2) by the MDRD formula (16). This degree of
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misclassification might lead to substantial underestimation of the risk-relationships
between true GFR and risk of death and cardiovascular events when eGFR is used (170).
Since 'true' GFR as not measured in any of these cohort studies the degree to which the
use of estimated GFR has biased these results cannot be determined. However, we aimed
to explore how the method used to estimate GFR might affect these associations by
identifying studies which assessed the relationship between eGFR or blood creatinine
concentration, and blood cystatin c concentration and all cause mortality. Searching
MEDLINE 1966 -1 April 2007 using the term 'cystatin', identified 5 studies assessing
blood cystatin concentration and death, of which 3 provided age and sex adjusted results
for both cystatin c and creatinine based GFR measures (Table 5.3). In each study, blood
cystatin c concentration was more strongly associated with an increased risk of death
than blood creatinine concentration of eGFR (Table 5.3). Possible explanations for these
findings include bias introduced by non-renal influences on blood cystatin c
concentration or a direct biological effect of cystatin c itself: However, it is possible that
the stronger relationship seen between blood cystatin c concentration and risk of death is
the result of a stronger relationship between blood cystatin c concentration and 'true'
GFR.
5.4.1.1 Impact of age on the relationship between eGFR and all cause mortality
The large Veteran's Affairs study observed a progressive weakening of the relative
increase in risk of death associated with lower eGFR as age increases (Figure 5.8). This
is consistent with a recently published analysis of a cohort of adults in whom creatinine
had been routinely measured, in which the relative risk of death associated with each K /
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DOQI CKD stage (16) among those aged 20-44 years was approximately 10 times that
observed among those aged over 85 years (273), and is in keeping with the effect of age
on the increased risk of cardiovascular death associated with ESKD, where young
individuals have an approximated 100 fold increase risk compared to a roughly 10 fold
increase in the elderly (274). However, this greater relative risk of death associated with
lower eGFR at younger ages is due to the very low background risk in these individuals,
and the absolute increase in risk of death associated with lower eGFR is substantially
greater at older ages (Figure 5.9 and (273)).
5.4.2 Potential sources ofheterogeneity
After taking into account proportional differences in eGFR at baseline, significant
heterogeneity was observed within the individual prospective cohort studies and also
within the routine data sources, which was not explained by the presence or absence of
prior cardiovascular disease. This heterogeneity could be the result of methodological
differences between the studies or differences in the study populations. Individual
patient data would be needed to properly explore the reasons for the between study
heterogeneity, although one methodological difference is worth mentioning here. In the
Kaiser-Permanente study (261), time-dependent techniques (rather than baseline eGFR)
were used to model the relationship between eGFR and risk which might explain the
somewhat stronger associations observed in this study (Figures 5.5 and 5.6).
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5.4.3 Possible explanations for the observed associations
The potential explanations for the increased risk of cardiovascular events and death
associated with lower eGFR include residual confounding, reverse causality or a causal
relationship. First, although almost all of the prospective cohort studies and many of the
other studies reported risk estimates adjusted not only for age and sex but also for
cholesterol, blood pressure, diabetes and smoking, we cannot discount the possibility
that residual confounding might remain. However, since the mechanisms by which
lower GFR might result in increased risk of cardiovascular disease would be expected to
include the development of hypertension and dyslipidaemia, it could equally be argued
that adjustment for these factors might attenuate a real relationship between GFR and
cardiovascular disease (275). Individual patient data meta-analysis could be used to
explore the effect of adjustment for such 'mediating' factors on the putative causal
pathway and other confounding factors. Second, cardiovascular disease might cause
reduced GFR (reverse causality) as a result of generalised atherosclerosis affecting the
coronary and renal arteries, nephrotoxic medication use or low output heart failure
causing reduced renal perfusion. While the observation that inverse risk-relationships
with eGFR were preserved in populations without known prior vascular disease might
suggest this to be unlikely, individual patient data meta-analysis of long term studies
examining early and late events separately would again be needed to properly explore
this possibility. Third, lower GFR might be a causal risk factor for cardiovascular
disease (23;276;277). Lower GFR is associated with traditional cardiovascular risk
factors such as increased blood pressure (278) and pro-atherogenic blood lipid profile
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(5;32) along with non-traditional cardiovascular risk factors such as raised inflammatory
markers (59), increased markers of platelet activation (54), higher blood homocysteine
concentration (279) and increased oxidative stress (63). However, in this meta-analysis,
lower eGFR was associated with a similar increase in the risk of both cardiovascular
disease and all cause mortality, suggesting that lower eGFR may also be associated with
non-vascular mortality.
5.4.4 Limitations ofthe study
A number of limitations of this study should be considered. First, a substantial number
of the routine data sources (280-290) and four of the randomized controlled trials (291 -
294) assessing all cause mortality in populations with prior vascular disease included
individuals with an acute illness at baseline. Exclusion of these studies, however, did not
materially alter the results: A 30% lower eGFR was associated with a 24% increase in
the risk of death in both randomised controlled trials and routine data sources after
excluding these studies, compared to a 23% increase when all studies were included.
Second, this meta-analysis relied on published risk estimates from whole populations.
We were, therefore, unable to explore the impact of adjusting for various confounders,
to analyse subgroups separately, or to examine the relationship between eGFR and
separate cardiovascular events or cause specific mortality. In addition, since the mean
eGFR in the reported reference groups was around 84 ml/min/1.73m2 this study cannot
make any comment on the impact of eGFR at higher eGFR values. Individual patient
data meta-analysis of these studies could potentially overcome these problems. However,
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since all these studies estimated GFR from serum creatinine concentration, which is only
weakly related to GFR among those with GFR > 60ml/min/1.73m2 (173), such analyses
may not reliably assess true risk-relationships across the range ofGFR values.
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5.5 Summary of key findings
■ A strong, graded, inverse relationship between lower eGFR levels and increased
risks of death and major vascular events was consistently observed in cohort studies,
randomized controlled trials and studies of routine data sources among people with
and without prior cardiovascular disease.
■ A 30% lower eGFR was associated with approximately a 20-30% increase in the risk
of both outcomes, although there was significant heterogeneity between the
individual prospective cohort studies and routine data sources.
■ These estimates may distort the true relationship between usual GFR and risk of
cardiovascular disease and death as a result of regression dilution bias and
misclassification due to inaccuracies of eGFR.
■ The relative importance of eGFR levels to all-cause mortality risk decreased as age
increased, but the absolute relevance of eGFR levels to risk was greatest at older
ages and among those with prior vascular disease.
■ Individual patient data meta-analysis is now needed to allow analysis of specific
subgroups, examination of individual outcomes, exploration of the effect of
adjustment for confounders and full assessment of the dose response relationship
although the large discrepancies between estimated and true GFR may still lead to an
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eGFR (in ml/min/1.73m") was estimated using the abbreviated MDRD equation
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Figure 5.2: Comparison of actual vs estimated mean eGFR levels in the comparison
groups
0 20 40 60 80 100 120
Predicted mean eGFR based on study cut-pomte
and numbers of participants in each group
Data restarted to the 10 studios that analysed >2 renal tunctbn groups, stated the cut-points
used to create them, and presented mean eGFR in each 70143
eGFR (in ml/min or ml/min/1.73m2) was estimated in the published studies using either an MDRD equation or the
CockCroft and Gault formula (Table 5.2)
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Figure 5.3: Results of the literature search
eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease
* Count of the number of studies, not the number of papers (different subsets of some study
populations appear in different papers while some papers present data on more than one study)
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Figure 5.10: Mean follow-up eGFR by percentile of the baseline distribution among
7697 patients allocated placebo in the MRC/BHF Heart Protection Study (follow-up 4-5
years later)
eGFR (in ml/min/1.73m2) was estimated using the abbreviated MDRD equation
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6.1 Summary of results
6.1.1 Measurement ofGFR in large scale epidemiological studies
This thesis describes the current methods by which GFR can be measured or estimated
(Chapter 1). Direct methods, in which GFR is assessed from the total plasma clearance,
or renal clearance, of an exogenous tracer compound using timed blood samples, with or
without urine collections, are accurate but time consuming and not suitable for large
scale epidemiological studies.
Indirect methods, in which GFR is estimated from a single measurement of the blood
concentration of an endogenous substance such as creatinine or cystatin c, are simple to
perform, but existing methods have two key limitations:
First, GFR estimated from blood creatinine and cystatin c concentrations are heavily
dependent on the laboratory method used, meaning that large biases can occur when the
laboratory methods and calibration are different to that used to develop the prediction
equations (161; 167).
Second, and more importantly, because of the reciprocal relationship with GFR and
inter-personal differences in rate of production, among healthy individuals any blood
concentration of creatinine or cystatin c is consistent with a wide range of the range of
possible GFR values (104; 156). Therefore, for any individual, GFR estimated by blood
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creatinine or cystatin c concentration may be widely discrepant from their 'true' GFR
(Chapters 1 and 2).
A novel method, in which total plasma iohexol clearance is measured using dried
capillary blood spots collected by study staff 2, 3 and 4 hours after intravenous injection,
accurately assesses GFR compared to traditional iohexol clearance using 3 timed plasma
samples (Chapter 2). Using only 2 capillary blood spots collected at 2 and 4 hours does
not lead to loss of accuracy (Chapter 2). This method has two key advantages for use in
large scale epidemiological studies: First, the method remains accurate when the dried
capillary blood spots are sent through the post, meaning that expensive transfer of
refrigerated samples or training and validation of local laboratories would not be
necessary for multi-centre studies (Chapter 2). Second, the blood spots could potentially
be completed by participants themselves at home substantially reducing the amount of
clinic time required. However, a cross-sectional feasibility study, in which volunteers
were asked to undertake the blood spot iohexol clearance (BSIC) procedure collecting 2
timed capillary blood spots themselves after the clinic (Chapter 3), raised a number of
problems associated with this method. One hundred percent of eligible participants were
successfully trained to collect suitable capillary blood samples during the clinic visit, of
whom 96% returned 2 analysable capillary blood spots and 90% found the blood spot
collection procedure acceptable. However, 21% of participants returned small or 'poor
quality' blood spots. In addition, there was statistical evidence the the sampling time had
not been accurately recorded by all participants and, more importantly, there was
evidence that large discrepancies between the actual sampling time and the recorded
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sampling time had occured. Although, when the blood spots are collected by study staff,
a simulated situation equivalent to one third of individuals misreporting the sample time
by 15 minutes or more had little effect on the accuracy of the blood spot iohexol
clearance method, larger discrepancies between actual and recorded sampling times
would substantially reduce test accuracy (Chapter 2). Improvements in the biochemical
methods to make use of small or poor quality spots, developement of an automated
timing device and further validation of the accuracy of the blood spot iohexol clearance
technique when samples are collected outside the clinic are needed before using this
method can be used in large scale studies.
6.1.2 Relationship between measures ofGFR and cardiovascular risk factors
In cross-sectional studies, chronic kidney disease is associated with hypertension (5;24),
a pro-atherogenic lipid profile (small dense LDL particles (317;318), lower HDL-
cholesterol (5;49) and increased blood triglycerides (5;43), higher blood concentrations
of C-reactive protein (52;54), fibrinogen (54;56) and homocysteine (27;240), while
increased body fat is an independent risk factor for the development of chronic kidney
disease in prospective studies (256;257). Animal studies suggest the association between
chronic kidney disease and hypertension (33) and dyslipidaemia (32) may be causal.
In a cross-sectional study of individuals with preserved GFR (mean ± standard deviation
GFR 103.1 ± 28.3 ml/min/1,73m2), in which GFR was assessed by blood spot iohexol
clearance, the MDRD formula and estimated from serum cystatin c concentration, one or
more of the GFR measure were positively correlated with blood HDL-cholesterol and
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apoliprotein At concentrations, and were inversely correlated with blood concentrations
of triglyceride, CRP, fibrinogen, and homocysteine (Chapter 4). No correlation was
observed between any of the GFR measures and diastolic blood pressure, systolic blood
pressure, or blood concentration of total-cholesterol, LDL-cholesterol or apo-lipoprotein
b in this sample, although the greater use of antihypertensive and lipid lowering
medication among those with lower GFR limits interpretation of these findings. The
magnitude of the change in these cardiovascular risk factors accompanying a
30ml/minl.73m2 lower GFR could be associated with a small but potentially clinically
relevant increase in risk of cardiovascular disease. This study considered how these
relationships might be affected by the method used to assess GFR. Surprisingly, GFR
measured by blood spot iohexol clearance (BSIC) was not more strongly related to
cardiovascular risk factors than that estimated from the MDRD formula, although this is
probably the result of inaccuracies in the BSIC method given the methodological issues
raised in chapter 3. GFR estimated from blood cystatin c concentration tended to be
more strongly correlated with blood lipids and inflammatory markers than GFR
measured by the other two methods. Measures of body fat were strongly correlated with
GFR estimated from cystatin c concentration, but not with either GFR estimated from
the MDRD equation or measured using blood spot iohexol clearance raising the
possibility that body fat might be related to cystatin c production.
6.1.3 Relationship between GFR and risk ofcardiovascular disease and death
No large scale prospective cohort studies have measured GFR directly. In a quantitative
meta-analysis of prospective studies assessing the relationship between GFR estimated
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from serum creatinine concentration (eGFR) and risk of death or cardiovascular events
(which included 4 061 003 and 1 372 820 individuals from 41 and 26 cohort studies for
the outcome of death and major vascular events respectively), a proportional reduction
in baseline eGFR was consistently associated with an increase risk of both outcomes,
whether the data for the study was collected as part of (i) a prospective cohort study (ii)
a randomized trial, or (iii) routine clinical or administrative practice (routine data
sources) (Chapter 5). For major vascular events this relationship was approximately log-
linear, whereas for death there was evidence ofnon-linearity, where small reductions in
eGFR of less than 20% were not associated with increased risk. Overall, a 30% lower
eGFR was associated with a 20-30% increase in risk of both death and vascular events
depending on the type of study examined, although significant heterogeneity was
observed between the results of the individual prospective cohort studies and routine
data sources for both outcomes, which was not explained by the presence of prior
vascular disease. One large routine data source provided data on the risk of death
associated with lower eGFR separately by age group. Although the relative impact of
eGFR was larger at younger age groups the absolute relevance of eGFR to risk of death
was greater at older ages and among those with prior vascular disease. In two large
routine data sources, which together contributed 85% of the available deaths, reduction
• *2in GFR was not associated with increased risk until eGFR was < 60 ml/min/1.73m ,
suggesting that the overall 20-30% increased risk of death associated with a 30% lower
eGFR may be an underestimate among those with chronic kidney disease. However, the
mean eGFR in the reference groups was around 84 ml/min/1.73m2 therefore this meta-
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analysis is not able to properly assess the dose response relationship between lower
eGFR and risk of death and vascular events across the range of GFR in the population.
Since GFR was not measured in these studies, but estimated from blood creatinine
concentration, misclassification between eGFR categories will occur. When the MDRD
formula is used to classify individuals into K / DOQI CKD stages (>90, 60-89, 30-59,
15-29, <15 ml/min/1.73m2(16)), nearly 30% of individuals are misclassified (21). This
degree ofmisclassification would lead to substantial distortion of the real relationship
between true GFR and risk of death and cardiovascular events when eGFR is used (170).
Large scale studies in which GFR is measured directly are needed to properly assess the
impact ofGFR on important outcomes such as death and cardiovascular morbidity, and
to reliably assess the interaction between GFR and cardiovascular risk factors.
6.2 Implications for observational epidemiology
In epidemiological studies, it may be important to assess GFR for 2 reasons:
First, one might wish to examine the relationship between GFR as an exposure variable
and a particular outcome. Second, assessment ofGFR would allow adjustment for GFR
in the examination of other exposures which correlated with GFR, for example blood
homocysteine concentration. The method used to measure GFR will affect both these
aims. When GFR is examined as an exposure, GFR estimated from blood creatinine or
cystatin c concentration may lead to an underestimate of the strength of the relationship
because ofmisclassification. While GFR estimated from the MDRD of Cockcroft Gault
formula is more informative than serum creatinine alone when assessing an individual's
GFR in clinical practice (16), an analysis of a cohort study adjusted for age, sex and race,
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eGFR provides no more information than one which uses blood creatinine concentration
alone. Since the accuracy of cystatin c is similar to that ofMDRD eGFR without the
inclusion of demographic variables, it is more useful in epidemiology. Flowever, both
measures predict GFR poorly among healthy individuals (Chapters 1 and 2). In cohort
studies examining the relationship between GFR and a particular outcome,
misclassification between GFR categories because of this inaccuracy will tend to bias
the results toward the null (170), while when eGFR is used to adjust for GFR, residual
confounding could remain.
In addition, non renal influences on the concentration of endogenous marker may
introduce specific biases. Blood cystatin c concentrations are strongly correlated with
body mass index, waist circumference and percentage body fat measured by single
frequency bioimpedance, when no correlation is observed between these measures of
body composition and either GFR measured by blood spot iohexol clearance or GFR
estimated by the MDRD formula (Chapter 4). In a large cross-sectional survey, cystatin
c was related to weight after adjustment for measured creatinine clearance (141). These
findings raise the possibility that body fat might be related to cystatin c production,
which could result in bias when cystatin c is used to assess the relationship between
GFR and cardiovascular disease.
6.3 Implications for clinical practice
GFR is rarely measured directly in clinical practice and is usually assessed from
measurement of serum creatinine concentration. GFR is usually assessed in clinical
practice in order to detect acute renal failure in acutely unwell patients, appropriately
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adjust the dose of drugs which are excreted via the kidney, or to identify individuals at
risk of developing end stage renal failure. In 2005 the Department of Health's National
Service Framework for Renal Services recommended that eGFR is used routinely in
clinical practice in preference to serum creatinine concentration alone. Identification of
individuals with chronic kidney disease based on estimated GFR (16), and assessment of
cardiovascular risk factors among these individuals, became a Quality Outcomes
Framework target for general practitioners in 2006. Since eGFR can be widely
discrepant from true GFR and, in healthy populations, may systematically underestimate
'true' GFR (Chapters 1 and 2), clinicians should be aware of the limitations using this
test to classify individuals as having a chronic disease.
This research would support the concept of reduced GFR as an independent risk factor
for cardiovascular disease (Chapter 5), although a number of substantial uncertainties
remain: The strength of the true relationship between GFR and risk of cardiovascular
events across the range of population GFR values remains poorly understood, if this
association is causal is unknown, and, if it is, how it is mediated and therefore how
might it be ameliorated is uncertain. Current practices identify a group of individuals
with reduced eGFR who could be recruited to future randomized clinical trials.
6.4 Future research
In assessing the hypothesis that small reductions in GFR result in clustering of
cardiovascular risk factors leading to increase risk of cardiovascular disease 3 areas of
further research should be considered.
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First, large scale prospective cohort studies of healthy individuals in which GFR is
measured directly are needed in order to properly assess the real relationship between
'true' GFR and cardiovascular outcomes across the population range of GFR. Potential
mechanisms for such an association could be explored by assessing the effect of
adjusting for cardiovascular risk factors which might be on the causal pathway such as
blood pressure, blood lipid concentrations, markers of inflammation and blood
homocysteine concentration. Blood spot iohexol clearance has potential for use in such
studies since, if participants can complete the blood sampling at home, it would
substantially reduce the clinic time required compared to traditional direct GFR methods,
and would allow transportation of samples at room temperature to a reference laboratory.
However, before this method can be used in large scale studies, biochemical methods
must be improved to enable accurate determination of iohexol concentration in small
and poor quality blood spots, and a method of automatically recording the sampling time,
perhaps with a combined timing and sampling device, must be developed. A large
population sample in which GFR is assessed accurately would also be important in
developing better indirect measures ofGFR by enabling;
■ Reliable assessment of the non-renal influences on blood cystatin c concentration,
■ Development of formulae which include demographic variables, creatinine and
cystatin c for potential use in clinical practice,
■ Storage of blood to allow assessment of new endogenous GFR markers which may
be more accurate than cystatin c
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Second, assessment of cardiovascular risk factors pre and post nephrectomy in healthy
kidney donors might help to determine the causal direction of the relationship between
lower GFR and cardiovascular risk factors.
Third, large scale clinical trials of cardio-protective interventions among individuals
with reduced GFR are needed to establish which interventions might prevent the excess
cardiovascular disease in this population.
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